Impact of emodin alone or in combination with ampicillin on methicillin-resistant Staphylococcus aureus biofilms in vitro

Impact of emodin alone or in combination with ampicillin on methicillin-resistant Staphylococcus aureus biofilms in vitro | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Article Impact of emodin alone or in combination with ampicillin on methicillin-resistant Staphylococcus aureus biofilms in vitro Maoying Zhao, Fuhong Chen, Wei Yang, Tao Yan, Qi Chen This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-5030207/v1 This work is licensed under a CC BY 4.0 License Status: Published Journal Publication published 01 Jul, 2025 Read the published version in Scientific Reports → Version 1 posted 8 You are reading this latest preprint version Abstract Methicillin-resistant Staphylococcus aureus (MRSA) is recognized as a significant global health concern. The development of resistance to a broad spectrum of antibiotics, particularly following biofilm formation, renders conventional therapeutic options for MRSA ineffective. Three MRSA clinical isolates were examined in vitro to assess their biofilm-forming capacity and the disruptive effects on pre-established biofilm (via crystal violet staining and scanning electron microscopy), and quantify extracellular DNA (eDNA) release after exposed to emodin alone or in combination with ampicillin. In addition, real-time PCR was employed to investigate the impact of emodin on the expression of biofilm-related genes in MRSA biofilms. The inhibitory effect of emodin on biofilm formation and disruption was observed in a dose dependent manner. The antagonistic activity of emodin in combination with ampicillin against MRSA biofilms was confirmed through adhesion assays. Real-time PCR analysis revealed that emodin, either alone or in combination with ampicillin, effectively downregulated the transcriptional levels of the biofilm-related genes fnbpB , clfA and atlA , but not icaA . In addition, drug treatment resulted in a significant reduction in eDNA release and protein contain in EPS (extracellular polymeric substances), which corresponded to the markedly decreased transcript level of atlA and fnbpB , respectively. These observations suggest that emodin, either alone or in combination with ampicillin, holds potential as a therapeutic approach for MRSA biofilm-related infections. Biological sciences/Biotechnology Biological sciences/Microbiology Health sciences/Diseases/Infectious diseases MRSA Emodin Ampicillin Antibiofilm activity Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Figure 8 Introduction Staphylococcus aureus is one of the most important pathogens responsible for a wide spectrum of diseases, the onset of which can be attributed to its production of various virulence factors 1 . The formation of biofilm by S. aureus is an additional pathogenic factor, as biofilms serve as reservoirs for persistent infections 2 , including implant-associated infections, chronic wounds, fibrotic lung infections and endocarditis 3 . The special three-dimensional structure of biofilms makes them difficult to be eliminated by antibiotics and host defense molecules, leading to a substantial increase in minimum inhibitory concentrations (MICs) compared to planktonic bacteria 4 . Moreover, the matrix of biofilm provides an ideal environment for closer cell-to-cell contact, which facilitates horizontal gene transfer, including plasmids containing genes resistance to several antibiotics 5 . The widespread use of indwelling medical devices (catheters, joint prostheses, heart stents, etc .) in clinical treatment has contributed to the increased incidences of S. aureus biofilm-related infections 6 . Currently, the only approach employed to address such cases is the replacement of colonized devices followed by treatment with antibiotics, which significantly escalates medical costs. Methicillin-resistant S. aureus (MRSA), a multidrug-resistant strain, has emerged as a leading cause of community- and hospital-acquired infections around the world 7 . The ability of MRSA to form biofilms is a crucial factor that can undermine the effectiveness of chemotherapy due to its inherent resistance and the protective polysaccharide barrier it possesses. Unfortunately, MRSA strains exhibit a higher propensity for biofilm formation than methicillin-sensitive Staphylococcus aureus (MSSA) strains under conditions of glucose deficiency 8 . Bacteria experience continuous exposure to sub-MICs of antibiotics at the beginning and end of treatment or during prolonged low-dose therapy. In addition, sub-MICs of β-lactam antibiotics induce the release of extracellular DNA (eDNA), an essential biofilm component, and promote biofilm formation in MRSA strains while having no effect on MSSA strains 9 . Vancomycin is the initial treatment option for MRSA-related infections. In recent years, the susceptibility of vancomycin to MRSA has been reported to dimmish and even disappear, especially with the appearance of vancomycin-intermediate and -resistant S. aureus (VISA and VRSA, respectively) 10 . Regarding biofilm-associated infections, several studies have reinforced the evidence of poor efficacy of vancomycin against S. aureus biofilms 11 , 12 . Due to the low efficiency and potential resistance development of resistance against S. aureus , efforts have been made to explore suitable combined effects of vancomycin with other antibiotics. However, there is limited evidence supporting the efficacy of the adjunctive use of rifampin and vancomycin, as there was no promise for the treatment of MRSA biofilm-related infections 13 . Similarly, there is an ongoing debate regarding the combined use of vancomycin with other antibiotics, such as linezolid, tigecycline and oxacillin 3 . Daptomycin, a cyclic lipopeptide molecule, has been reported to be effective against VRSA biofilm-associated infections 7 and capable of eradicating S. aureus from an existing biofilm alone 14 or when used in combination with other drugs 15 – 17 . However, there have also been reports of the failure of daptomycin against biofilm-producing S. aureus strains in vitro and in animal models 18 – 20 . Recently, natural antimicrobials, primary derived from plants, have been identified to exhibit antibiofilm properties against S. aureus . Nevertheless, the efficacy of these antimicrobials is generally weaker than that of conventional drugs produced by bacteria and fungi. However, natural antimicrobials, unlike conventional antibiotics, do not exert selection pressure on bacteria and can synergistically enhance the activity of other antibiotics. For instance, baicalein or hamamelitannin in combination with vancomycin 21 , 22 , quinine with ciprofloxacin 23 and xanthohumol with oxacillin 24 have shown potent synergistic effects. Emodin, a compound extracted from Polygonum cuspidatum and Rheum palmatum , has been investigated for its ability to inhibit cell proliferation and ER stress 25 , prevent obesity and cancer 26 , and attenuate Alzheimer’s disease 27 . Additionally, emodin has exhibited significant activity against Haemophilus parasuis , Pseudomonas aeruginosa , Streptococcus suis and even S. aureus 28 , 29 . One study demonstrated that emodin reduced S. aureus biofilms by preventing eDNA release and downregulating the expression of biofilm-related genes 30 . However, the synergistic antibiofilm effectiveness of emodin and other traditional antibiotics on MRSA has not been reported. Therefore, the objective of this study was to evaluate the congruous efficacy of emodin in combination with ampicillin, a wide used β-lactam antibiotics, against biofilm cultures of MRSA and to unveil the mechanism of action. Results Determination of minimum inhibitory concentrations and minimal bactericidal concentrations in suspension and biofilm The MICs of emodin alone against these three strains in suspension cells were 16, 32 µg/ml and 32 µg/ml, respectively. Notably, emodin demonstrated consistent MBCs of 512 µg/ml. In comparison, ampicillin exhibited higher MIC values of 64, 128 µg/ml and 128 µg/ml against the same strains. Its bactericidal activity was also strain-dependent, with MBCs of 512, 1024 and 1024 µg/ml, respectively, reflecting a less uniform efficacy profile than emodin (see Table 1 ). According to the testing standard described in our previous study 31 , and based on the microtiter plate assay, it was determined that all isolates of MRSA exhibited moderate biofilm production. It seemed that eradicating bacteria in the biofilm of MRSA were challenging, as the minimum biofilm inhibition concentrations (MBICs) and the minimum biofilm eradication concentration (MBBCs) were all more than 512 µg/ml for emodin alone and above 1024 µg/ml for Amp alone. Furthermore, the interaction between Amp and emodin was also determined among these S. aureus strains. And the results indicated a synergistic efficacy in the MRSA strain 18 − 9 and 19 − 13 (as shown in Table 2 ). Table 1 Susceptibility of Amp or Emodin against the MRSA strains in suspension. Strains Amp (µg/ml) Emodin (µg/ml) MIC MBC MBIC MBBC MIC MBC MBIC MBBC MRSA 18 − 9 64 512 >1024 >1024 16 512 >512 >512 MRSA 19 − 10 128 1024 >1024 >1024 32 512 >512 >512 MRSA 19 − 13 128 1024 >1024 >1024 32 512 >512 >512 Table 2 Fractional inhibitory concentration index (FICI) Values for combination between Amp and Emodin Strains Amp (µg/ml) Emodin (µg/ml) FICI Interpretation a MRSA 18 − 9 16 4 0.5 SYN MRSA 19 − 10 4 16 0.53 IND MRSA 19 − 13 4 8 0.28 SYN a For the FICI model, synergism (SYN) was determined as an FICI of ≤ 0.5, antagonism (ANT) as an FICI of >4.0 and indifference (IND) as an FICI of >0.5 to 4.0. Antibiofilm activity against S. aureus biofilm formation MRSA biofilm formation was compared between strains cultured with and without drugs, specifically MICs and sub-MICs of Amp or emodin, for 48 h. As shown in Fig. 1 B, emodin reduced the cell attachment in a dose-dependent manner across all strains. Moreover, at only 1/4 MIC, emodin markedly inhibited 29.03% (MRSA 18 − 9), 28.73% (MRSA 19 − 10) and 48.15% (MRSA 19 − 13) of biofilm formation, similar to the reduction observed with up to 1/2 MIC of Amp under the same conditions (Figs. 1 A and 1 B). Hence, this suggests that emodin may be more effective than Amp in disrupting S. aureus biofilm formation. To determine the combined efficacy, three major groups were exposed to 1/8 MIC, 1/4 MIC and 1/2 MIC of Amp alone. In addition, S. aureus in each group was treated with (1/4 to 1 MIC) or without emodin simultaneously. Various combinations yielded diverse consequences for these three MRSA strains. However, as depicted in Fig. 2 , the addition of sub-MIC emodin in each group significantly enhanced the inhibition efficacy of biofilm formation, with more than 55% biofilm inhibition observed in the presence of 1/2 MIC emodin in every group. Combined efficacy in mature biofilms of S. aureus In a second set of experiments, the disruption of the mature biofilms (48 hours of growth in the absence of drugs) by the addition of Amp plus emodin at different concentrations for another 48 hours was evaluated. Figure 3 A illustrated that increasing the concentration of Amp had little impact on reducing the biofilm formation of the tested MRSA strains. In contrast, a dose-dependent decrease in biofilm levels was observed with increasing concentrations of emodin (Fig. 3 B). The combined efficacy of Amp and emodin in destroying preformed biofilms also varied depending on the strain. However, at 1/2 MIC, compared to the controls, emodin exhibited a maximum of 50% (MRSA 19 − 13), 42% (MRSA 19 − 10), 24% (MRSA 18 − 9) inhibition of biofilm formation (Fig. 4 ). Observation of MRSA biofilm morphology by SEM Figure 5 displayed the morphology of the bacterial biofilm captured by SEM. In the control group, which received only 1/4 MIC of Amp, the bacteria were predominantly observed as dense cellular aggregates throughout the entire field of view. As the concentration of emodin was increased (ranging from 1/4 to 1 MIC) in the control group, the substances were largely, but not entirely, eliminated, aligning with the quantitative findings presented in Fig. 2 . Gene expression analysis To explore whether the influence manifested the transcriptional levels, the expression of the ica operon and important adhesion and eDNA-related genes were detected using RT-qPCR, and the results were shown in Fig. 6 . Increasing the concentration of emodin did not result in a significant difference in the expression levels of icaA compared to the control blank (p > 0.05). However, fnbpB , clfA and atlA were downregulated in a dose-dependent manner (Fig. 6 A). More importantly, the transcriptional levels of fnbpB and clfA were significantly decreased by 2.68- and 3.85-fold (p < 0.05) when exposed to 1/2 MIC emodin, respectively. Interestingly, the transcriptional levels of AtlA, the major S. aureus autolysin protein, were markedly inhibited by 8- to 21-fold after treatment with all subinhibitory concentrations of emodin (p < 0.001). Figure 6 B illustrated the gene activity following exposure to a combination of Amp and emodin. Compared to the control group exposed solely to 1/4 MIC Amp, the expression levels of icaA , fnbpB , clfA and atlA were significantly decreased when both drugs were administered together. Similar to the results shown in Fig. 6 A, the addition of 1/4 and 1/2 MIC emodin in the culture medium exhibited great significance in the transcript levels of clfA and atlA (p < 0.001). Analysis of slime production In S. aureus , the production of slime, which encompasses polysaccharide substrates, is intricately associated with the formation of biofilms. When Congo Red interacts with these polysaccharide substrates, it elicits a color transformation from red to black upon incubation. The findings revealed that the black pigmentation surrounding the colonies remained unaltered across varying concentrations of emodin (Supplementary Fig. 1) and when emodin was combined with 1/8 MIC Amp. However, a notably discernible reduction in coloration was observed when the colonies were treated with a combination of emodin and 1/4 MIC of Amp (Fig. 7 A-D). Qualitative analysis of proteins in EPS EPS is a complex mixture primarily composed of polysaccharides, proteins, lipids, and nucleic acids. These components interact to form a highly hydrated and dynamic matrix that provides structural support and functional properties to the biofilm. The adhesive properties of EPS enable bacteria to adhere to surfaces, forming the foundation for biofilm development. To further understand the role of proteins in EPS, Micro BCA Protein Assay was used to compare the content of proteins between the different treatment of the antimicrobial drugs. As shown in Fig. 7 E, a notable decrease in the amount of protein was observed in MRSA cells treated with 1/4 to 1/2 MIC emodin, compared to cells treated only with Amp in each group (p < 0.001). Qualitative analysis of eDNA release and autolysis assay According to previous studies, eDNA, which is released through the autolysis of a small population of biofilm cells, constitutes a critical substrate in biofilms during the initial bacterial adhesion and surface aggregation. In this study, a notable decrease in the amount of eDNA release was observed in MRSA 19 − 10 cells treated with emodin at concentrations ranging from 1/4 to 1 MIC, compared to control cells (Fig. 8 A). The amounts of eDNA in the cell-free supernatants from biofilms treated with the combination of antimicrobial agents were shown in Fig. 8 B. Remarkably, a great reduction observed in eDNA release from biofilms was observed when treated with 1/4 to 1/2 MIC emodin, compared to cells treated only with Amp in each group (p < 0.001). To further assess the effect of emodin, MRSA 19 − 10 cells were treated with various concentrations of emodin, and the rate of autolysis induced by the nonionic detergent Triton X-100 was compared an untreated control culture (Fig. 8 C). After 210 min, the OD 600 values of the cells treated with 1/8 MIC, 1/4 MIC, 1/2 MIC and 1 MIC emodin were 73.30%, 73.46%, 80.16% and 81.94% of the initial value, respectively. In contrast, the control group displayed highly active autolysis, with an OD 600 value of 65.27%. Discussion The remarkable tolerance of bacteria in biofilms to antibiotics, host defense, nutritional deficiency and heat shock underscores the urgent need for the development of antibacterial agents or treatment options to address the chronic and recurrent infections that they cause. With advanced methodologies for separation and isolation procedures, an increasing number of natural products from plants have been considered candidates for biofilm-associated infections. In the current study, emodin alone or in combination with Amp was found to exhibit anti-MRSA biofilm activity through the downregulation of biofilm-related genes ( icaA , fnbpB , clfA and atlA ). β-lactam antibiotics have traditionally been the preferred treatment for serious invasive infections caused by S. aureus until the emergence of MRSA, which has acquired a genetic element called mecA . mecA encodes an alternative penicillin-binding protein 2a (PBP2a) with diminished affinity for β-lactam antibiotics. However, MRSA susceptible to combinations of a β-lactam and compounds that disrupt the essential scaffold for PBP2a integrity 32 . Consequently, we have selected Amp as a therapeutic partner for emodin to combat MRSA biofilm activity. Our intention is to augment the anti-MRSA biofilm efficacy of the two antimicrobial agents by employing a combination therapy strategy. A previous study had already investigated the effects of emodin on biofilm formation of S. aureus CMCC26003, a standard MSSA strain 30 . However, the antibiofilm activity of emodin alone or in combination with β-lactam antibiotics against MRSA is poorly understood. The MIC of emodin against S. aureus was reported to be 8 µg/ml and 7.8 µg/ml in previous studies 30 . In this work, the MIC against MRSA planktonic cells was 16 or 32 µg/ml (Table 1 ). This discrepancy in MIC values may be attributed to the varying bioactivity of emodin yielded by different manufacturers and distinct gene backgrounds. It is well known that MRSA is generally more resistant to antibiotics compared to MSSA 33 . Our results showed that emodin exhibited a concentration-dependent antibiofilm efficacy against all tested strains and showed a greater inhibition in the formation of biofilms at the same fold of MIC than that of Amp (Fig. 1 A and 1 B). As shown in Fig. 2 , the combination of 1/4 MIC or 1/2 MIC Amp plus 1/2 MIC emodin significantly affected the biofilm formation of the tested strains. Importantly, the biofilms formed by MRSA strain 19 − 13 at all tested concentrations were significantly lower (p < 0.001) compared to the untreated controls. Therefore, we believed that emodin is capable of sensitizing Amp to MRSA biofilm formation in a dose-dependent manner. In the clinic, biofilm-associated infections always occur without prevention 21 . Once biofilms have formed completely, they become more challenging to eradicate, requiring higher concentrations of antimicrobial agents due to the blocked diffusion 34 . Our findings, as indicated by crystal violet quantification, revealed that emodin was able to eradicate 28.55% of MRSA strain 19 − 10 and 34.75% of MRSA strain 19 − 13 mature biofilms only at 1/4-fold MIC. Beyond this concentration, the eradication effects became more pronounced, and statistical significance (p < 0.001) were observed. Additionally, an escalating inhibition ration against mature biofilms was observed with the increasing concentrations of both antimicrobial agents in MRSA strain. While the addition of 1/2 MIC emodin was enough to eradicate preformed biofilms, even a higher concentration of Amp (from 1/8 to 1/2 MIC) was required in MRSA strain 19 − 13. To explore the molecular mechanism of emodin, the gene expression profiles of cells that were not treated and cells that were treated with emodin were compared using real-time qPCR analysis. Staphylococcal biofilms are surrounded by a self-produced extracellular matrix that consists of proteins, eDNA and polysaccharide intercellular adhesion (PIA). PIA synthesis is mediated by the ica operon. Therefore, downregulating ica gene expression could be an effective strategy to prevent S. aureus biofilm formation 30 . Nevertheless, it has been reported that MRSA strains can exhibit an ica -independent biofilm phenotype in vitro, while clinical MSSA isolates have been identified as PNAG-dependent biofilm phenotype 35 . Moreover, most MRSA biofilms consist of eDNA and adhesins, whereas MSSA strains typically form biofilms that contain polysaccharides in their matrices 9 . In our study, the CRA plate assay demonstrated that emodin had no discernible effect on slime production unless it was co-administered with 1/4 MIC Amp (Supplementary Table 1 and Fig. 7 A-D). This finding was in accordance with the observation of a slight decrease in ica expression within the emodin-treated groups when Ampicillin was present at a sub-MIC level. Microbial surface components recognizing adhesive matrix molecules (MSCRAMMs), such as fibronectin-binding proteins (Fnbps) and clumping factor A (ClfA), have been known to play an important role in the initial stage of biofilm formation 36 , 37 . Interestingly, Fnbps have been shown to compensate for the absence of PIA in facilitating biofilm formation in the icaADBC -independent biofilm phenotypes 36 . Moreover, this Fnbp-mediated biofilm is particularly common among highly virulent MRSA isolates, highlighting the significance of PIA-independent biofilm formation in MRSA strains. The micro-BCA method, derived from the established BCA method, exhibits enhanced sensitivity and is particularly well-suited for low-dose determinations. Our findings revealed a decreasing trend in the total protein content of EPS with an increasing concentration of emodin, within the sub-MIC range of Amp (as illustrated in the Fig. 7 E). Consistent with previous studies 38 – 40 , our results demonstrated that increased expression levels of fnbpB were associated with a reduction in biofilm formation. As shown in Fig. 6 , the transcriptional levels of clfA , which shared 25% sequence identity with fnbpB in its A domain, were decreased by emodin in a dose-dependent manner. The importance of eDNA within biofilms potentially hinges on its multifaceted roles: facilitating antibiotic resistance mechanisms, guiding nutrient localization during periods of starvation, and serving as a reservoir for the gene pool that enables horizontal gene transfer 41 , 42 . In the case of MRSA strains, eDNA release in biofilms is predominantly mediated by the autolysin protein AtlA, which is produced when a small population of biofilm cells undergo autolysis 43 . Initially described as a secreted enzyme responsible for maintaining cell wall metabolism during cell division and growth, AtlA’s participation in biofilm development has been demonstrated in various biofilm models 43 . The role of AtlA-mediated lysis in biofilm development was revealed in some biofilm models 44 . In our study, we observed a significant 7.1- and 4.2-fold decrease in the expression of the atlA gene when exposing the cells to a concentration of only 1/4 MIC emodin (Fig. 6 ), both in the absence or presence of 1/2 MIC Amp, aligning with the observed changes in eDNA levels (Fig. 8 ). Pharmacological investigations have underscored the therapeutic promise of emodin in traditional medicine for managing conditions such as inflammation and cancer. Concurrently, accumulating evidence of its organ-specific toxicity, particularly hepatotoxicity and nephrotoxicity, had prompted heightened safety concerns in clinical applications 45 , 46 . Concomitant administration of two or more pharmacological agents, synergistically augment treatment efficacy while attenuating systemic toxicities. This combinatorial strategy confers multifaceted benefits, including enhanced therapeutic index, reduced risk of drug resistance development, and improved patient compliance through tailored dosing paradigms. Our study, which investigated the combinatorial anti-biofilm activity of emodin and ampicillin against MRSA through a synergistic administration paradigm, constituted an exploratory approach to concurrent drug delivery strategies. On the other hand, nanotechnology-based drug delivery platforms have emerged as revolutionizing pharmaceutics by enhancing drug solubility, improving biocompatibility, extending circulation duration, and reducing toxicity through targeted design. A recent study demonstrated that the in situ delivery of emodin via Pluronic F-127 not only enhances its aqueous solubility but also enables targeted, prolonged release at the targeted site 47 . Subsequently, we will aim to elucidate the pronounced anti-biofilm efficacy of emodin through a targeted nanoparticle delivery system. In summary, the present work demonstrated the potential of emodin, an anthraquinone derived from R. palmatum , to prevent biofilm formation and disrupt the mature biofilm of MRSA strains alone or in combination with Amp. This inhibitory effect was observed through the downregulation of fnbpB , clfA and atlA genes. Unfortunately, to date, no reliable animal model of biofilm infection has been established, which has precluded us from further validating the synergistic anti-MRSA biofilm infection effect of emodin and ampicillin in vivo. This limitation will be a critical focus of our future research endeavors. Methods Ethical statement Ethical permission was approved by the Ethics Committee of Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, with the reference No. 2019SQ011. Participants provided written informed consent to participate in this study. All methods were carried out in accordance with relevant guidelines and regulations. Bacterial strains and reagents In this study, all S. aureus isolates were collected from patients at the local hospital in Hangzhou city. The antibiotic resistance profiles of these isolates were tested against 16 drugs, as recommended by the Clinical and Laboratory Standards Institute (CLSI) criteria. Three MRSA strains, exhibited resistance to oxacillin with a MIC of 8 μg/ml and were subsequently identified as MRSA through detection of the specific mecA gene. Bacterial stocks of each strain were maintained at -80°C in tryptic soy broth (TSB) containing 20% glycerol (v/v). To initiate experiments, all the strains were thawed and subcultured in tryptic soy agar (TSA) for 18-24 hours. Emodin and ampicillin (Amp) were obtained from Sangon Biotech (Shanghai, China) and prepared as stock solutions in DMSO (Sigma-Aldrich, St. Louis, Missouri, USA) and ultrapure water, respectively. Antimicrobial activity of S. aureus in suspension The MICs and MBCs were determined using twofold dilutions. The MIC was expressed as the lowest concentration that showed no visible growth in the medium. The MBC was defined as the lowest concentration that showed no microbial growth on agar. Each isolate in each drug was tested in triplicate. Interactions between Amp and emodin against S. aureus in suspension A checkerboard microdilution method was employed to examine the combined efficacy of Amp and emodin against MRSA. Serial twofold dilutions were prepared in Mueller Hinton (MH) broth, covering a range from 1/32- to 4-fold MIC for Amp, and from 1/64- to 2-fold MIC for emodin. The 96-well plates were incubated at 37°C for 18-24 hours. To evaluate the effect of the combination, the fractional inhibitory concentration index (FICI) was computed using the following formula 48 : FICI A = MIC of A in combination/MIC of A alone FICI= FICI Amp + FICI Emodin FICI≤0.5, synergy; 0.54.0, antagonism. Establishment of biofilms Biofilm formation was measured as previously described 31 . Briefly, individual clones were cultivated in TSB and incubated in an orbital shaker (180 rpm) at 37°C for 6 hours. One percent of the S. aureus culture was used for all assays. The bacterial cultures were adjusted to a turbidity of 0.5 McFarland scale using phosphate buffered saline (PBS). Subsequently, the cultures were diluted 1:100 into TSB supplemented with 0.5% glucose and added to each well of a sterile 96-well flat-bottom microtiter plate (Corning Incorporated, Corning, New York, USA), which was incubated at 37°C for 40-48 hours under static conditions. Following incubation, the planktonic cells were removed by washing, and the remaining adherent bacterial cells in each well were stained with 100 µl of 0.1% crystal violet solution (Sangon Biotech, Shanghai, China). To dissolve the plates, 100 µl of 33% glacial acetic acid (v/v) was added to per well, and the absorption was subsequently measured at 490 nm using an iMark microplate absorbance reader (Bio-Rad Laboratories, Hercules, California, USA). Antimicrobial activity of S. aureus in biofilms Cultivated biofilms were gently washed with PBS to remove planktonic cells, and then incubated for an additional 24 hours at 37°C in the presence of antimicrobial agents. Subsequently, the antimicrobial drugs were then removed and the biofilms were washed. PBS-treated biofilms were served as a positive control. The biofilms on the bottom were scrapped and washed with 250 µl PBS, while the contents of wells (10 µl) were mixed with warm MH broth and incubated for 24 hours at 37°C. The MBIC was defined as the lowest concentration that inhibited visible growth of the bacteria in the medium. The samples that exhibited no growth on agar at the lowest concentration were recorded as the MBBC 49 . Biofilm disruption To determine the impacts on mature biofilms, S. aureus was allowed to form biofilms on 96-well plates in the absence of the aforementioned drugs. Subsequently, the nonadherent cells were removed, and fresh TSB+0.5% glucose media, along with various concentrations of agents, were added to each well independently or in combination for an additional 40-48 hours at 37°C. The amounts within biofilms were quantified using crystal violet staining as described above. Scanning electron microscopy assay MRSA cells (1.0 × 10 6 CFU/ml) were cultivated in fresh TSB+0.5% glucose media, housed in 12-well plates with glasses coverslips. Various sub-MIC concentrations of emodin, along with 1/4 MIC of Amp, were introduced into the wells and incubated at 37 °C. Following an incubation period ranging from 40 to 48 hours, the supernatant was discarded, and the biofilms were washed gently with PBS. Subsequently, 2.5% glutaraldehyde was administered to fix the biofilms at 4 °C overnight. After washing with PBS, the samples were dehydrated through a series of ethanol concentrations (30%, 50%, 70%, 80%, 95%, and 100%), with each step lasting 10 min each. Finally, the samples were coated with gold and examined using a scanning electron microscope (Hitachi Regulus8100, Tokyo, Japan). RNA isolation and real-time PCR analysis Bacterial cells scraped from MRSA biofilms that were treated with antimicrobial agents alone or in combination, were suspended in 25 µg/ml lysostaphin (Sigma-Aldrich, St. Louis, Missouri, USA) and incubated at 37°C for 3 hours. Then, RNA extraction was performed using the RNeasy Mini Kit (Qiagen, Dusseldorf, Germany) according to the manufacturer’s instructions. The concentration of RNA was quantified using a NanoDrop spectrophotometer. cDNA was obtained by transcription of 150 ng of the total RNA using PrimeScript™ RT Master Mix (Takara, Tokyo, Japan). Real-time PCR analysis was performed on a thermal cycler (Roche Group, Basel, Switzerland) for the genes icaA , fnbpB , clfA and atlA using PCR mix (Takara, Tokyo, Japan) at a predefined ratio. Cycle threshold (Ct) values of all the tested genes were normalized using the Ct value of the housekeeping gene gyrB ( gyrase B ). Finally, the expression levels were quantified by the 2 (–ΔΔCt) method 39 . Primer sequences of the genes used in this study are given in Supplementary Table S1. Slime production assay Slime production assays were conducted using Congo Red agar (CRA), as previously described 50 .Congo red agar (CRA) plates consisted of brain-heart infusion (37 g/L), sucrose (36 g/L), and agar (15 g/L). After autoclaving the medium, the separated Congo Red dye (0.8 g/L) , together with control and the antimicrobial drugs were added to the agar medium when the temperature was cooled to 55 °C. The mixture was then poured into plates and allowed to solidify for use. Overnight cultures of MRSA cells (10 μl) were dropped on CRA plates and incubated for 24 h at 37 °C before imaging. Three independent experiments were conducted. EPS extraction and analysis The EPS was extracted by using a modified method as described 51 . Briefly, the biofilms of S. aureus were grown in 96-well microtiter plates (Corning, Costar, USA) treated with different concentrations of emodin or a combination with ampicillin for 24 hours. The medium was discarded, and the biofilms was washed with PBS before dissolved in PBS solution to prepare EPS. Protein in EPS extractions was determined quantitatively using the Micro BCA Protein Assay Kit (Sangon Biotech, Shanghai, China) according to the manufacturer. Extraction of eDNA eDNA was extracted from biofilms and quantified using a modified version of the method described in a previous study. Briefly, the biofilms of S. aureus were grown on 6-well plates and treated with either emodin alone or a combination with ampicillin for 24 hours. After chilling at 4°C for 1 hour, 10 μl 0.5 M EDTA was added. The medium was discarded, and the unwashed biofilms were scraped and resuspended in Tris-EDTA (TE) buffer (10 mM Tris, 1 mM EDTA). The suspension was vigorously vortexed for 1 hour. After centrifugation (14000 rpm for 10 min), the supernatants were transferred to new tubes, and the remaining bacteria were removed via a 0.22 μm filter (Millipore Corporation, Billerica, Massachusetts, USA). The filtered supernatants were subjected to 1.5% (w/v) agarose gel electrophoresis and quantified by mixing 10 μl of supernatant with fluorescent dyes from Qubit (Invitrogen Life Technologies, Carlsbad, California, USA) for quantifying the DNA. The fluorescence of the DNA-dye interaction was measured using a Qubit 2.0 Fluorometer according to the manufacturer's instructions. Triton X-100-induced autolysis assays Concentrations of 1/8 MIC, 1/4 MIC, 1/2 MIC or 1 MIC emodin were added to the cultures when the MRSA strain reached an optical density at 600 nm (OD 600 ) of 0.3. The cultures were then incubated with shaking at 37°C until the OD 600 reached 0.7 in control cultures. The cells, including those treated with emodin, were harvested by centrifugation and washed once with cold distilled PBS. The resulting cell pellet was resuspended in 0.05 M Tris–HCl (pH 7.0) containing 0.05% (v/v) Triton X-100. Afterwards, the cell suspension was then incubated at 37°C with shaking, and the OD 600 was determined at various time intervals. Data availability All data generated or analyzed during this study are included in this published article and its supplementary information files. Statistical analysis All experiments were carried out in triplicate, and values are presented as the mean ± standard deviation (SD). Statistical analysis was performed using Student’s t-test (*p < 0.05, **p < 0.01, ***p < 0.001). Declarations Acknowledgements This work was supported by Zhejiang Provincial Natural Science Foundation of China (Grant No. ZCLTGY24H2001 to Q.C.), the National Natural Science Foundation of China (Grant No. 81700768 to Q.C.), and the Special Supporting Program of Agriculture and Social Development from Hangzhou Municipal Science & Technology Bureau (Grant No.202203B34 to Q.C.). Author contributions Q.C. designed the experiments. Q.C. performed data analysis. Q.C. and M.Y.Z. performed the experiments. Q.C., F.H.C. W.Y. and T.Y. critically revised the paper. Q.C. supervised the project. Q.C. wrote the manuscript. All authors approved the final manuscript. Additional Information Competing Interests: The authors declare no competing interests. References Howden, B. P. et al. Staphylococcus aureus host interactions and adaptation. Nat Rev Microbiol 21 , 380-395 (2023). Kosmeri, C., Giapros, V., Serbis, A., Balomenou, F. & Baltogianni, M. Antibiofilm Strategies in Neonatal and Pediatric Infections. Antibiotics (Basel) 13 2024). Bhattacharya, M., Wozniak, D. J., Stoodley, P. & Hall-Stoodley, L. Prevention and treatment of Staphylococcus aureus biofilms. Expert Rev Anti Infect Ther 13 , 1499-1516 (2015). Howlin, R. P. et al. Antibiotic-loaded synthetic calcium sulfate beads for prevention of bacterial colonization and biofilm formation in periprosthetic infections. Antimicrob Agents Chemother 59 , 111-120 (2015). Flemming, H. C. et al. Biofilms: an emergent form of bacterial life. Nat Rev Microbiol 14 , 563-575 (2016). Suresh, M. K., Biswas, R. & Biswas, L. An update on recent developments in the prevention and treatment of Staphylococcus aureus biofilms. Int J Med Microbiol 309 , 1-12 (2019). Craft, K. M., Nguyen, J. M., Berg, L. J. & Townsend, S. D. Methicillin-resistant Staphylococcus aureus (MRSA): antibiotic-resistance and the biofilm phenotype. Medchemcomm 10 , 1231-1241 (2019). Fitzpatrick, F., Humphreys, H. & O'Gara, J. P. Environmental regulation of biofilm development in methicillin-resistant and methicillin-susceptible Staphylococcus aureus clinical isolates. J Hosp Infect 62 , 120-122 (2006). Mlynek, K. D. et al. Effects of Low-Dose Amoxicillin on Staphylococcus aureus USA300 Biofilms. Antimicrob Agents Chemother 60 , 2639-2651 (2016). Fait, A., Silva, S. F., Abrahamsson, J. A. H. & Ingmer, H. Staphylococcus aureus response and adaptation to vancomycin. Adv Microb Physiol 85 , 201-258 (2024). Di Domenico, E. G. et al. Microbial biofilm correlates with an increased antibiotic tolerance and poor therapeutic outcome in infective endocarditis. BMC Microbiol 19 , 228 (2019). Oliva, A., Stefani, S., Venditti, M. & Di Domenico, E. G. Biofilm-Related Infections in Gram-Positive Bacteria and the Potential Role of the Long-Acting Agent Dalbavancin. Front Microbiol 12 , 749685 (2021). Tremblay, S., Lau, T. T. & Ensom, M. H. Addition of rifampin to vancomycin for methicillin-resistant Staphylococcus aureus infections: what is the evidence? Ann Pharmacother 47 , 1045-1054 (2013). Smith, K., Perez, A., Ramage, G., Gemmell, C. G. & Lang, S. Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J Antimicrob Agents 33 , 374-378 (2009). Dhand, A. et al. Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. Clin Infect Dis 53 , 158-163 (2011). Miro, J. M. et al. High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 56 , 4511-4515 (2012). Kullar, R. et al. A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. J Antimicrob Chemother 68 , 2921-2926 (2013). Revest, M. et al. New in vitro and in vivo models to evaluate antibiotic efficacy in Staphylococcus aureus prosthetic vascular graft infection. J Antimicrob Chemother 71 , 1291-1299 (2016). Parra-Ruiz, J., Vidaillac, C., Rose, W. E. & Rybak, M. J. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Antimicrob Agents Chemother 54 , 4329-4334 (2010). Cirioni, O. et al. Daptomycin and rifampin alone and in combination prevent vascular graft biofilm formation and emergence of antibiotic resistance in a subcutaneous rat pouch model of staphylococcal infection. Eur J Vasc Endovasc Surg 40 , 817-822 (2010). Chen, Y. et al. Baicalein Inhibits Staphylococcus aureus Biofilm Formation and the Quorum Sensing System In Vitro. PLoS One 11 , e0153468 (2016). Brackman, G. et al. The Quorum Sensing Inhibitor Hamamelitannin Increases Antibiotic Susceptibility of Staphylococcus aureus Biofilms by Affecting Peptidoglycan Biosynthesis and eDNA Release. Sci Rep 6 , 20321 (2016). Abreu, A. C., Saavedra, M. J., Simoes, L. C. & Simoes, M. Combinatorial approaches with selected phytochemicals to increase antibiotic efficacy against Staphylococcus aureus biofilms. Biofouling 32 , 1103-1114 (2016). Rozalski, M. et al. Antiadherent and antibiofilm activity of Humulus lupulus L. derived products: new pharmacological properties. Biomed Res Int 2013 , 101089 (2013). Tian, N. et al. Emodin mitigates podocytes apoptosis induced by endoplasmic reticulum stress through the inhibition of the PERK pathway in diabetic nephropathy. Drug Des Devel Ther 12 , 2195-2211 (2018). Xing, Y. X. et al. Anti-Cancer Effects of Emodin on HepG2 Cells as Revealed by (1)H NMR Based Metabolic Profiling. J Proteome Res 17 , 1943-1952 (2018). Du, C. et al. Emodin attenuates Alzheimer's disease by activating the protein kinase C signaling pathway. Cell Mol Biol (Noisy-le-grand) 65 , 32-37 (2019). Li, L. et al. The antibacterial activity and action mechanism of emodin from Polygonum cuspidatum against Haemophilus parasuis in vitro. Microbiol Res 186-187 , 139-145 (2016). Liu, M. et al. The direct anti-MRSA effect of emodin via damaging cell membrane. Appl Microbiol Biotechnol 99 , 7699-7709 (2015). Yan, X. et al. The effect of emodin on Staphylococcus aureus strains in planktonic form and biofilm formation in vitro. Arch Microbiol 199 , 1267-1275 (2017). Chen, Q. et al. Biofilm formation and prevalence of adhesion genes among Staphylococcus aureus isolates from different food sources. Microbiologyopen 9 , e00946 (2020). Shang, W. et al. beta-Lactam Antibiotics Enhance the Pathogenicity of Methicillin-Resistant Staphylococcus aureus via SarA-Controlled Lipoprotein-Like Cluster Expression. mBio 10 , e00880-00819 (2019). Jo, A. & Ahn, J. Phenotypic and genotypic characterisation of multiple antibiotic-resistant Staphylococcus aureus exposed to subinhibitory levels of oxacillin and levofloxacin. BMC Microbiol 16 , 170 (2016). Feldman, M., Smoum, R., Mechoulam, R. & Steinberg, D. Antimicrobial potential of endocannabinoid and endocannabinoid-like compounds against methicillin-resistant Staphylococcus aureus. Sci Rep 8 , 17696 (2018). Pozzi, C. et al. Methicillin resistance alters the biofilm phenotype and attenuates virulence in Staphylococcus aureus device-associated infections. PLoS Pathog 8 , e1002626 (2012). O'Neill, E. et al. A novel Staphylococcus aureus biofilm phenotype mediated by the fibronectin-binding proteins, FnBPA and FnBPB. J Bacteriol 190 , 3835-3850 (2008). O'Brien, L. M., Walsh, E. J., Massey, R. C., Peacock, S. J. & Foster, T. J. Staphylococcus aureus clumping factor B (ClfB) promotes adherence to human type I cytokeratin 10: implications for nasal colonization. Cell Microbiol 4 , 759-770 (2002). Zheng, Z. et al. Antimicrobial activity of 1,3,4-oxadiazole derivatives against planktonic cells and biofilm of Staphylococcus aureus. Future Med Chem 10 , 283-296 (2018). Selvaraj, A., Jayasree, T., Valliammai, A. & Pandian, S. K. Myrtenol Attenuates MRSA Biofilm and Virulence by Suppressing sarA Expression Dynamism. Front Microbiol 10 , 2027 (2019). Valliammai, A. et al. 5-Dodecanolide interferes with biofilm formation and reduces the virulence of Methicillin-resistant Staphylococcus aureus (MRSA) through up regulation of agr system. Sci Rep 9 , 13744 (2019). Abdelhady, W. et al. Reduced vancomycin susceptibility in an in vitro catheter-related biofilm model correlates with poor therapeutic outcomes in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 57 , 1447-1454 (2013). Gloag, E. S. et al. Self-organization of bacterial biofilms is facilitated by extracellular DNA. Proc Natl Acad Sci U S A 110 , 11541-11546 (2013). McCarthy, H. et al. Methicillin resistance and the biofilm phenotype in Staphylococcus aureus. Front Cell Infect Microbiol 5 , 1 (2015). Schwartz, K., Ganesan, M., Payne, D. E., Solomon, M. J. & Boles, B. R. Extracellular DNA facilitates the formation of functional amyloids in Staphylococcus aureus biofilms. Mol Microbiol 99 , 123-134 (2016). Wang, S. et al. Hepatotoxic metabolites in Polygoni Multiflori Radix- Comparative toxicology in mice. Front Pharmacol 13 , 1007284 (2022). Cui, J., Wang, S., Bi, S., Zhou, H. & Sun, L. Emodin-based Regulation and Control of Serum Complement C5a, Oxidative Stress, and Inflammatory Responses in Rats with Urosepsis via AMPK/SIRT1. Iran J Allergy Asthma Immunol 23 , 550-562 (2024). Yao, Y. et al. Emodin in-situ delivery with Pluronic F-127 hydrogel for myocardial infarction treatment: Enhancing efficacy and reducing hepatotoxicity. Life Sci 354 , 122963 (2024). Oo, T. Z., Cole, N., Garthwaite, L., Willcox, M. D. & Zhu, H. Evaluation of synergistic activity of bovine lactoferricin with antibiotics in corneal infection. J Antimicrob Chemother 65 , 1243-1251 (2010). Guo, N. et al. The synergy of berberine chloride and totarol against Staphylococcus aureus grown in planktonic and biofilm cultures. J Med Microbiol 64 , 891-900 (2015). Park, I., Lee, J. H., Ma, J. Y., Tan, Y. & Lee, J. Antivirulence activities of retinoic acids against Staphylococcus aureus. Front Microbiol 14 , 1224085 (2023). Salisbury, A. M., Chen, R., Mullin, M., Foulkes, L. & Percival, S. L. The Effects of a Concentrated Surfactant Gel on Biofilm EPS. Surg Technol Int 36 , 31-35 (2020). Additional Declarations No competing interests reported. Supplementary Files Supplementary.docx SupplymentaryFigure1.jpg SupplemetaryFig2.tif Cite Share Download PDF Status: Published Journal Publication published 01 Jul, 2025 Read the published version in Scientific Reports → Version 1 posted Editorial decision: Revision requested 23 May, 2025 Editor assigned by journal 23 May, 2025 Editor invited by journal 23 May, 2025 Reviews received at journal 03 May, 2025 Reviewers agreed at journal 23 Apr, 2025 Reviewers invited by journal 22 Apr, 2025 Submission checks completed at journal 22 Apr, 2025 First submitted to journal 07 Apr, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-5030207","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Article","associatedPublications":[],"authors":[{"id":446193174,"identity":"a9e8c25b-3f9c-41ee-b974-7682a4a2c7e4","order_by":0,"name":"Maoying Zhao","email":"","orcid":"","institution":"Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University","correspondingAuthor":false,"prefix":"","firstName":"Maoying","middleName":"","lastName":"Zhao","suffix":""},{"id":446193175,"identity":"fb4a5d50-f147-498e-9673-dfcfb3eae01a","order_by":1,"name":"Fuhong Chen","email":"","orcid":"","institution":"Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University","correspondingAuthor":false,"prefix":"","firstName":"Fuhong","middleName":"","lastName":"Chen","suffix":""},{"id":446193176,"identity":"3adee4ae-b94c-4a85-820d-5364f9fe5850","order_by":2,"name":"Wei Yang","email":"","orcid":"","institution":"Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University","correspondingAuthor":false,"prefix":"","firstName":"Wei","middleName":"","lastName":"Yang","suffix":""},{"id":446193177,"identity":"840220b6-523f-42fd-be7d-f245bdfcb3aa","order_by":3,"name":"Tao Yan","email":"","orcid":"","institution":"Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University","correspondingAuthor":false,"prefix":"","firstName":"Tao","middleName":"","lastName":"Yan","suffix":""},{"id":446193178,"identity":"d69e589f-6c28-40f6-8768-d725ab7ff902","order_by":4,"name":"Qi Chen","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA1klEQVRIiWNgGAWjYDACCRBhwJDAwN7AeCCBNC08BxhI0cIA1CKRwHCAKB38s5uPPXhTwJAnP/PxgwMP2w7nMbAfProBryV3jqUbzjFgKGacnWZwILHtcDEDT1raDXxaDCRyzKR5DBgSm6UTwFoSGyR4zAhoyf8G1tImefwDsVpy2MBaeiR4iLRF4kaamSTQL4kzeHIKDiScS09sI+QX/hnJzyTe/GFInN9+fOPDH2XWif3sh4/h1QIGPAz/IQxGNgYGNoLKIVpg4A9R6kfBKBgFo2CEAQDGWkwXLwYR8gAAAABJRU5ErkJggg==","orcid":"","institution":"Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University","correspondingAuthor":true,"prefix":"","firstName":"Qi","middleName":"","lastName":"Chen","suffix":""}],"badges":[],"createdAt":"2024-09-04 09:04:03","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-5030207/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-5030207/v1","draftVersion":[],"editorialEvents":[{"content":"https://doi.org/10.1038/s41598-025-06800-5","type":"published","date":"2025-07-01T15:57:11+00:00"}],"editorialNote":"","failedWorkflow":false,"files":[{"id":81214212,"identity":"0562009f-51ea-4326-843d-f4048e2d3781","added_by":"auto","created_at":"2025-04-23 14:04:09","extension":"png","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":469224,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eEffects of drugs on biofilm formation of MRSA strain. \u003c/strong\u003eBiofilm formation by MRSA in presence of Amp (A) and emodin (B), in 96-well plates after 40-48 h, was assessed by crystal violet staining. Each bar indicates the mean values ± SE from at least three independent experiments. Control group means no Amp added (in Fig 1A.) and no emodin (in Fig 1B) added. *p \u0026lt; 0.05, **p \u0026lt; 0.01, ***p \u0026lt; 0.001, compared with their respective control groups.\u003c/p\u003e","description":"","filename":"figure1.png","url":"https://assets-eu.researchsquare.com/files/rs-5030207/v1/252724d29c30440b2ca74d33.png"},{"id":81213689,"identity":"8322f96f-fd48-42bd-8f5c-1fe6d4461ad9","added_by":"auto","created_at":"2025-04-23 13:56:09","extension":"png","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":419783,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eCombined effects of drugs on biofilm formation of MRSA strains. \u003c/strong\u003eBiofilm formation by MRSA in presence of Amp and emodin, in 96-well plates after 40-48 h, was assessed by crystal violet staining. Each bar indicates the mean values ± SE from at least three independent experiments. Control group means no emodin added. *p \u0026lt; 0.05, **p \u0026lt; 0.01, ***p \u0026lt; 0.001, compared with their respective control groups.\u003c/p\u003e","description":"","filename":"figure2.png","url":"https://assets-eu.researchsquare.com/files/rs-5030207/v1/00753a4938fdf8d6725fca8d.png"},{"id":81213692,"identity":"1ece8ad8-d525-4c40-b5e4-abd49150bd4b","added_by":"auto","created_at":"2025-04-23 13:56:09","extension":"png","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":487843,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eEffects of drugs on biofilm disruption of MRSA strain. \u003c/strong\u003eMature biofilm, incubated with fresh TSB+0.5% glucose media containing Amp (A) and emodin (B) for another 40-48 h, was assessed by crystal violet staining. Each bar indicates the mean values ± SE from at least three independent experiments. Control group means no Amp added (in Fig 3A.) and no Emodin added (in Fig 3B.). *p \u0026lt; 0.05, **p \u0026lt; 0.01, ***p \u0026lt; 0.001, compared with their respective control groups.\u003c/p\u003e","description":"","filename":"figure3.png","url":"https://assets-eu.researchsquare.com/files/rs-5030207/v1/b82833c86eb0e1872e6f4e42.png"},{"id":81215930,"identity":"83819a93-33ab-4880-a82b-0e87a9fbac51","added_by":"auto","created_at":"2025-04-23 14:20:09","extension":"png","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":335887,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eCombined effects of drugs on biofilm disruption of MRSA strains. \u003c/strong\u003eMature biofilm, incubated with fresh TSB+0.5% glucose media containing Amp and emodin for another 40-48 h, was assessed by crystal violet staining. Each bar indicates the mean values ± SE from at least three independent experiments. Control group means no emodin added. *p \u0026lt; 0.05, **p \u0026lt; 0.01, ***p \u0026lt; 0.001, compared with their respective control groups.\u003c/p\u003e","description":"","filename":"figure4.png","url":"https://assets-eu.researchsquare.com/files/rs-5030207/v1/144f0a67974605f1babd7308.png"},{"id":81213700,"identity":"1dce6acf-f858-4647-b000-12c6c169708d","added_by":"auto","created_at":"2025-04-23 13:56:09","extension":"png","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":6113600,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eSEM analysis of MRSA 19-10 biofilm. \u003c/strong\u003eSEM images of biofilm formed by MRSA 19-10 that had been incubated with 1/4 MIC of Amp together with 1/4 to 1 MIC concentrations of emodin for40-48 h. Scale bars in the figures represented 10 μm.\u003c/p\u003e","description":"","filename":"figure5.png","url":"https://assets-eu.researchsquare.com/files/rs-5030207/v1/c72365b6a83cc64c1a4fcd9e.png"},{"id":81213706,"identity":"355e1428-bb49-4967-9d03-bdc83b184547","added_by":"auto","created_at":"2025-04-23 13:56:09","extension":"png","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":304744,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eExpression of biofilm-related genes in MRSA 19-10 in response to emodin or in combination with Amp. \u003c/strong\u003eThe normalized fold expression changes in biofilm-related genes following exposure to emodin alone or in combination with Amp for 24 h was plotted against control biofilms without exposure to Emodin (A) or with only exposure to Amp (B) using \u003cem\u003egyrB\u003c/em\u003e as the reference gene. Each bar indicates the mean values ± SE from at least three independent experiments. *p \u0026lt; 0.05, **p \u0026lt; 0.01, ***p \u0026lt; 0.001, compared with their respective control groups.\u003c/p\u003e","description":"","filename":"figure6.png","url":"https://assets-eu.researchsquare.com/files/rs-5030207/v1/7696cf902b59603261150faa.png"},{"id":81213731,"identity":"2279e400-d150-460c-b4f0-094d1d2eaeff","added_by":"auto","created_at":"2025-04-23 13:56:10","extension":"png","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":11504638,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eEffect of drugs on PIA formation and on extracellular proteins. \u003c/strong\u003eA) MRSA 19-10 was grown on Congo red medium and incubated with 1/4 MIC of Amp together with 1/4 to 1 MIC concentrations of emodin; B) Analysis the effect of drugs on extracellular proteins by micro BCA method. Each bar indicates the mean values ± SE from at least three independent experiments. *p \u0026lt; 0.05, **p \u0026lt; 0.01, ***p \u0026lt; 0.001, compared with their respective control groups.\u003c/p\u003e","description":"","filename":"figure7.png","url":"https://assets-eu.researchsquare.com/files/rs-5030207/v1/53e4b0ab88828412a1405a07.png"},{"id":81214225,"identity":"b5701e4e-60e4-4473-b622-808b6dec57fd","added_by":"auto","created_at":"2025-04-23 14:04:09","extension":"png","order_by":8,"title":"Figure 8","display":"","copyAsset":false,"role":"figure","size":1050100,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eEffects of drugs on eDNA release and autolysis of MRSA strain 19-10. \u003c/strong\u003eA-B)\u003cstrong\u003e \u003c/strong\u003eThe amount of eDNA in the cell-free supernatants from MRSA 19-10 biofilms treated with emodin alone or in combination with Amp was measured by spectrophotometry (upper panel) and agarose gel electrophoresis (down panel); C) Triton X-100 was used to stimulate autolysis in MRSA 19-10 cells grown in the absence or presence of various concentrations of emodin. The data were from a single representative experiment and were reproduced at least three times.\u003c/p\u003e","description":"","filename":"figure8.png","url":"https://assets-eu.researchsquare.com/files/rs-5030207/v1/a867b7bd572696416d60f7c1.png"},{"id":86179819,"identity":"cbe5de34-7dc3-42db-afdf-03eb8dfc3f55","added_by":"auto","created_at":"2025-07-07 16:19:41","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":20352440,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-5030207/v1/898b7a7c-b1b8-4622-9a2a-39dc46b690f4.pdf"},{"id":81213690,"identity":"75cbf2b9-7140-4d9d-832a-6eb86d78bc20","added_by":"auto","created_at":"2025-04-23 13:56:09","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":21635,"visible":true,"origin":"","legend":"","description":"","filename":"Supplementary.docx","url":"https://assets-eu.researchsquare.com/files/rs-5030207/v1/86e34416a464601a9e446292.docx"},{"id":81215447,"identity":"35869bf6-5c28-4953-86aa-d144d47f3261","added_by":"auto","created_at":"2025-04-23 14:12:09","extension":"jpg","order_by":2,"title":"","display":"","copyAsset":false,"role":"supplement","size":750850,"visible":true,"origin":"","legend":"","description":"","filename":"SupplymentaryFigure1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-5030207/v1/053ac7621a6919c16fa996cc.jpg"},{"id":81214214,"identity":"b7db36d3-6656-4465-be0d-b8fdd824137c","added_by":"auto","created_at":"2025-04-23 14:04:09","extension":"tif","order_by":3,"title":"","display":"","copyAsset":false,"role":"supplement","size":486864,"visible":true,"origin":"","legend":"","description":"","filename":"SupplemetaryFig2.tif","url":"https://assets-eu.researchsquare.com/files/rs-5030207/v1/0a3d95e934d2f38c05b5c260.tif"}],"financialInterests":"No competing interests reported.","formattedTitle":"Impact of emodin alone or in combination with ampicillin on methicillin-resistant Staphylococcus aureus biofilms in vitro","fulltext":[{"header":"Introduction","content":"\u003cp\u003e \u003cem\u003eStaphylococcus aureus\u003c/em\u003e is one of the most important pathogens responsible for a wide spectrum of diseases, the onset of which can be attributed to its production of various virulence factors \u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e\u003c/sup\u003e. The formation of biofilm by \u003cem\u003eS. aureus\u003c/em\u003e is an additional pathogenic factor, as biofilms serve as reservoirs for persistent infections \u003csup\u003e\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e, including implant-associated infections, chronic wounds, fibrotic lung infections and endocarditis \u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e. The special three-dimensional structure of biofilms makes them difficult to be eliminated by antibiotics and host defense molecules, leading to a substantial increase in minimum inhibitory concentrations (MICs) compared to planktonic bacteria \u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e. Moreover, the matrix of biofilm provides an ideal environment for closer cell-to-cell contact, which facilitates horizontal gene transfer, including plasmids containing genes resistance to several antibiotics \u003csup\u003e\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e\u003c/sup\u003e. The widespread use of indwelling medical devices (catheters, joint prostheses, heart stents, \u003cem\u003eetc\u003c/em\u003e.) in clinical treatment has contributed to the increased incidences of \u003cem\u003eS. aureus\u003c/em\u003e biofilm-related infections \u003csup\u003e\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e. Currently, the only approach employed to address such cases is the replacement of colonized devices followed by treatment with antibiotics, which significantly escalates medical costs.\u003c/p\u003e \u003cp\u003eMethicillin-resistant \u003cem\u003eS. aureus\u003c/em\u003e (MRSA), a multidrug-resistant strain, has emerged as a leading cause of community- and hospital-acquired infections around the world \u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e. The ability of MRSA to form biofilms is a crucial factor that can undermine the effectiveness of chemotherapy due to its inherent resistance and the protective polysaccharide barrier it possesses. Unfortunately, MRSA strains exhibit a higher propensity for biofilm formation than methicillin-sensitive \u003cem\u003eStaphylococcus aureus\u003c/em\u003e (MSSA) strains under conditions of glucose deficiency \u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e\u003c/sup\u003e. Bacteria experience continuous exposure to sub-MICs of antibiotics at the beginning and end of treatment or during prolonged low-dose therapy. In addition, sub-MICs of β-lactam antibiotics induce the release of extracellular DNA (eDNA), an essential biofilm component, and promote biofilm formation in MRSA strains while having no effect on MSSA strains \u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eVancomycin is the initial treatment option for MRSA-related infections. In recent years, the susceptibility of vancomycin to MRSA has been reported to dimmish and even disappear, especially with the appearance of vancomycin-intermediate and -resistant \u003cem\u003eS. aureus\u003c/em\u003e (VISA and VRSA, respectively) \u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e. Regarding biofilm-associated infections, several studies have reinforced the evidence of poor efficacy of vancomycin against \u003cem\u003eS. aureus\u003c/em\u003e biofilms \u003csup\u003e\u003cspan citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e,\u003cspan citationid=\"CR12\" class=\"CitationRef\"\u003e12\u003c/span\u003e\u003c/sup\u003e. Due to the low efficiency and potential resistance development of resistance against \u003cem\u003eS. aureus\u003c/em\u003e, efforts have been made to explore suitable combined effects of vancomycin with other antibiotics. However, there is limited evidence supporting the efficacy of the adjunctive use of rifampin and vancomycin, as there was no promise for the treatment of MRSA biofilm-related infections \u003csup\u003e\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e. Similarly, there is an ongoing debate regarding the combined use of vancomycin with other antibiotics, such as linezolid, tigecycline and oxacillin \u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e. Daptomycin, a cyclic lipopeptide molecule, has been reported to be effective against VRSA biofilm-associated infections \u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e and capable of eradicating \u003cem\u003eS. aureus\u003c/em\u003e from an existing biofilm alone \u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e\u003c/sup\u003e or when used in combination with other drugs \u003csup\u003e\u003cspan additionalcitationids=\"CR16\" citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR17\" class=\"CitationRef\"\u003e17\u003c/span\u003e\u003c/sup\u003e. However, there have also been reports of the failure of daptomycin against biofilm-producing \u003cem\u003eS. aureus\u003c/em\u003e strains in vitro and in animal models \u003csup\u003e\u003cspan additionalcitationids=\"CR19\" citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eRecently, natural antimicrobials, primary derived from plants, have been identified to exhibit antibiofilm properties against \u003cem\u003eS. aureus\u003c/em\u003e. Nevertheless, the efficacy of these antimicrobials is generally weaker than that of conventional drugs produced by bacteria and fungi. However, natural antimicrobials, unlike conventional antibiotics, do not exert selection pressure on bacteria and can synergistically enhance the activity of other antibiotics. For instance, baicalein or hamamelitannin in combination with vancomycin \u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e,\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e, quinine with ciprofloxacin \u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e and xanthohumol with oxacillin \u003csup\u003e\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e\u003c/sup\u003e have shown potent synergistic effects. Emodin, a compound extracted from \u003cem\u003ePolygonum cuspidatum\u003c/em\u003e and \u003cem\u003eRheum palmatum\u003c/em\u003e, has been investigated for its ability to inhibit cell proliferation and ER stress \u003csup\u003e\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e, prevent obesity and cancer \u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e, and attenuate Alzheimer\u0026rsquo;s disease \u003csup\u003e\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e. Additionally, emodin has exhibited significant activity against \u003cem\u003eHaemophilus parasuis\u003c/em\u003e, \u003cem\u003ePseudomonas aeruginosa\u003c/em\u003e, \u003cem\u003eStreptococcus suis\u003c/em\u003e and even \u003cem\u003eS. aureus\u003c/em\u003e \u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e,\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e. One study demonstrated that emodin reduced \u003cem\u003eS. aureus\u003c/em\u003e biofilms by preventing eDNA release and downregulating the expression of biofilm-related genes \u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e. However, the synergistic antibiofilm effectiveness of emodin and other traditional antibiotics on MRSA has not been reported.\u003c/p\u003e \u003cp\u003eTherefore, the objective of this study was to evaluate the congruous efficacy of emodin in combination with ampicillin, a wide used β-lactam antibiotics, against biofilm cultures of MRSA and to unveil the mechanism of action.\u003c/p\u003e"},{"header":"Results","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eDetermination of minimum inhibitory concentrations and minimal bactericidal concentrations in suspension and biofilm\u003c/h2\u003e \u003cp\u003eThe MICs of emodin alone against these three strains in suspension cells were 16, 32 \u0026micro;g/ml and 32 \u0026micro;g/ml, respectively. Notably, emodin demonstrated consistent MBCs of 512 \u0026micro;g/ml. In comparison, ampicillin exhibited higher MIC values of 64, 128 \u0026micro;g/ml and 128 \u0026micro;g/ml against the same strains. Its bactericidal activity was also strain-dependent, with MBCs of 512, 1024 and 1024 \u0026micro;g/ml, respectively, reflecting a less uniform efficacy profile than emodin (see Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). According to the testing standard described in our previous study \u003csup\u003e\u003cspan citationid=\"CR31\" class=\"CitationRef\"\u003e31\u003c/span\u003e\u003c/sup\u003e, and based on the microtiter plate assay, it was determined that all isolates of MRSA exhibited moderate biofilm production. It seemed that eradicating bacteria in the biofilm of MRSA were challenging, as the minimum biofilm inhibition concentrations (MBICs) and the minimum biofilm eradication concentration (MBBCs) were all more than 512 \u0026micro;g/ml for emodin alone and above 1024 \u0026micro;g/ml for Amp alone. Furthermore, the interaction between Amp and emodin was also determined among these \u003cem\u003eS. aureus\u003c/em\u003e strains. And the results indicated a synergistic efficacy in the MRSA strain 18\u0026thinsp;\u0026minus;\u0026thinsp;9 and 19\u0026thinsp;\u0026minus;\u0026thinsp;13 (as shown in Table\u0026nbsp;\u003cspan refid=\"Tab2\" class=\"InternalRef\"\u003e2\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab1\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 1\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eSusceptibility of Amp or Emodin against the MRSA strains in suspension.\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"9\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c6\" colnum=\"6\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c7\" colnum=\"7\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c8\" colnum=\"8\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c9\" colnum=\"9\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\" morerows=\"1\" rowspan=\"2\"\u003e \u003cp\u003eStrains\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"4\" nameend=\"c5\" namest=\"c2\"\u003e \u003cp\u003eAmp (\u0026micro;g/ml)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colspan=\"4\" nameend=\"c9\" namest=\"c6\"\u003e \u003cp\u003eEmodin (\u0026micro;g/ml)\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eMIC\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eMBC\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eMBIC\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eMBBC\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c6\"\u003e \u003cp\u003eMIC\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c7\"\u003e \u003cp\u003eMBC\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c8\"\u003e \u003cp\u003eMBIC\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c9\"\u003e \u003cp\u003eMBBC\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMRSA 18\u0026thinsp;\u0026minus;\u0026thinsp;9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e64\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e512\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026gt;1024\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u0026gt;1024\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e512\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u0026gt;512\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e\u0026gt;512\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMRSA 19\u0026thinsp;\u0026minus;\u0026thinsp;10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e128\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1024\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026gt;1024\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u0026gt;1024\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e32\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e512\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u0026gt;512\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e\u0026gt;512\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMRSA 19\u0026thinsp;\u0026minus;\u0026thinsp;13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e128\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e1024\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c4\"\u003e \u003cp\u003e\u0026gt;1024\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003e\u0026gt;1024\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c6\"\u003e \u003cp\u003e32\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c7\"\u003e \u003cp\u003e512\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c8\"\u003e \u003cp\u003e\u0026gt;512\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c9\"\u003e \u003cp\u003e\u0026gt;512\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003cp\u003e \u003cdiv class=\"gridtable\"\u003e\u003ctable float=\"Yes\" id=\"Tab2\" border=\"1\"\u003e \u003ccaption language=\"En\"\u003e \u003cdiv class=\"CaptionNumber\"\u003eTable 2\u003c/div\u003e \u003cdiv class=\"CaptionContent\"\u003e \u003cp\u003eFractional inhibitory concentration index (FICI) Values for combination between Amp and Emodin\u003c/p\u003e \u003c/div\u003e \u003c/caption\u003e \u003ccolgroup cols=\"5\"\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c1\" colnum=\"1\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c2\" colnum=\"2\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c3\" colnum=\"3\"\u003e\u003c/div\u003e \u003cdiv align=\"char\" char=\".\" class=\"colspec\" colname=\"c4\" colnum=\"4\"\u003e\u003c/div\u003e \u003cdiv align=\"left\" class=\"colspec\" colname=\"c5\" colnum=\"5\"\u003e\u003c/div\u003e \u003cthead\u003e \u003ctr\u003e \u003cth align=\"left\" colname=\"c1\"\u003e \u003cp\u003eStrains\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c2\"\u003e \u003cp\u003eAmp (\u0026micro;g/ml)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c3\"\u003e \u003cp\u003eEmodin (\u0026micro;g/ml)\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c4\"\u003e \u003cp\u003eFICI\u003c/p\u003e \u003c/th\u003e \u003cth align=\"left\" colname=\"c5\"\u003e \u003cp\u003eInterpretation \u003csup\u003ea\u003c/sup\u003e\u003c/p\u003e \u003c/th\u003e \u003c/tr\u003e \u003c/thead\u003e \u003ctbody\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMRSA 18\u0026thinsp;\u0026minus;\u0026thinsp;9\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.5\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSYN\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMRSA 19\u0026thinsp;\u0026minus;\u0026thinsp;10\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e16\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.53\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eIND\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003ctr\u003e \u003ctd align=\"left\" colname=\"c1\"\u003e \u003cp\u003eMRSA 19\u0026thinsp;\u0026minus;\u0026thinsp;13\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c2\"\u003e \u003cp\u003e4\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c3\"\u003e \u003cp\u003e8\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"char\" char=\".\" colname=\"c4\"\u003e \u003cp\u003e0.28\u003c/p\u003e \u003c/td\u003e \u003ctd align=\"left\" colname=\"c5\"\u003e \u003cp\u003eSYN\u003c/p\u003e \u003c/td\u003e \u003c/tr\u003e \u003c/tbody\u003e \u003c/colgroup\u003e \u003ctfoot\u003e \u003ctr\u003e\u003ctd colspan=\"5\"\u003e\u003csup\u003ea\u003c/sup\u003e For the FICI model, synergism (SYN) was determined as an FICI of \u0026le;\u0026thinsp;0.5, antagonism (ANT) as an FICI of \u0026gt;4.0 and indifference (IND) as an FICI of \u0026gt;0.5 to 4.0.\u003c/td\u003e\u003c/tr\u003e \u003c/tfoot\u003e \u003c/table\u003e\u003c/div\u003e \u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eAntibiofilm activity against S. aureus biofilm formation\u003c/h3\u003e\n\u003cp\u003eMRSA biofilm formation was compared between strains cultured with and without drugs, specifically MICs and sub-MICs of Amp or emodin, for 48 h. As shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB, emodin reduced the cell attachment in a dose-dependent manner across all strains. Moreover, at only 1/4 MIC, emodin markedly inhibited 29.03% (MRSA 18\u0026thinsp;\u0026minus;\u0026thinsp;9), 28.73% (MRSA 19\u0026thinsp;\u0026minus;\u0026thinsp;10) and 48.15% (MRSA 19\u0026thinsp;\u0026minus;\u0026thinsp;13) of biofilm formation, similar to the reduction observed with up to 1/2 MIC of Amp under the same conditions (Figs.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA and \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB). Hence, this suggests that emodin may be more effective than Amp in disrupting \u003cem\u003eS. aureus\u003c/em\u003e biofilm formation. To determine the combined efficacy, three major groups were exposed to 1/8 MIC, 1/4 MIC and 1/2 MIC of Amp alone. In addition, \u003cem\u003eS. aureus\u003c/em\u003e in each group was treated with (1/4 to 1 MIC) or without emodin simultaneously. Various combinations yielded diverse consequences for these three MRSA strains. However, as depicted in Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e, the addition of sub-MIC emodin in each group significantly enhanced the inhibition efficacy of biofilm formation, with more than 55% biofilm inhibition observed in the presence of 1/2 MIC emodin in every group.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e\n\u003ch3\u003eCombined efficacy in mature biofilms of S. aureus\u003c/h3\u003e\n\u003cp\u003eIn a second set of experiments, the disruption of the mature biofilms (48 hours of growth in the absence of drugs) by the addition of Amp plus emodin at different concentrations for another 48 hours was evaluated. Figure\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA illustrated that increasing the concentration of Amp had little impact on reducing the biofilm formation of the tested MRSA strains. In contrast, a dose-dependent decrease in biofilm levels was observed with increasing concentrations of emodin (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eB). The combined efficacy of Amp and emodin in destroying preformed biofilms also varied depending on the strain. However, at 1/2 MIC, compared to the controls, emodin exhibited a maximum of 50% (MRSA 19\u0026thinsp;\u0026minus;\u0026thinsp;13), 42% (MRSA 19\u0026thinsp;\u0026minus;\u0026thinsp;10), 24% (MRSA 18\u0026thinsp;\u0026minus;\u0026thinsp;9) inhibition of biofilm formation (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003e).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003e \u003c/p\u003e\n\u003ch3\u003eObservation of MRSA biofilm morphology by SEM\u003c/h3\u003e\n\u003cp\u003eFigure \u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003e displayed the morphology of the bacterial biofilm captured by SEM. In the control group, which received only 1/4 MIC of Amp, the bacteria were predominantly observed as dense cellular aggregates throughout the entire field of view. As the concentration of emodin was increased (ranging from 1/4 to 1 MIC) in the control group, the substances were largely, but not entirely, eliminated, aligning with the quantitative findings presented in Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e\n\u003ch3\u003eGene expression analysis\u003c/h3\u003e\n\u003cp\u003eTo explore whether the influence manifested the transcriptional levels, the expression of the \u003cem\u003eica\u003c/em\u003e operon and important adhesion and eDNA-related genes were detected using RT-qPCR, and the results were shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003e. Increasing the concentration of emodin did not result in a significant difference in the expression levels of \u003cem\u003eicaA\u003c/em\u003e compared to the control blank (p\u0026thinsp;\u0026gt;\u0026thinsp;0.05). However, \u003cem\u003efnbpB\u003c/em\u003e, \u003cem\u003eclfA\u003c/em\u003e and \u003cem\u003eatlA\u003c/em\u003e were downregulated in a dose-dependent manner (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eA). More importantly, the transcriptional levels of \u003cem\u003efnbpB\u003c/em\u003e and \u003cem\u003eclfA\u003c/em\u003e were significantly decreased by 2.68- and 3.85-fold (p\u0026thinsp;\u0026lt;\u0026thinsp;0.05) when exposed to 1/2 MIC emodin, respectively. Interestingly, the transcriptional levels of AtlA, the major \u003cem\u003eS. aureus\u003c/em\u003e autolysin protein, were markedly inhibited by 8- to 21-fold after treatment with all subinhibitory concentrations of emodin (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001). Figure\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eB illustrated the gene activity following exposure to a combination of Amp and emodin. Compared to the control group exposed solely to 1/4 MIC Amp, the expression levels of \u003cem\u003eicaA\u003c/em\u003e, \u003cem\u003efnbpB\u003c/em\u003e, \u003cem\u003eclfA\u003c/em\u003e and \u003cem\u003eatlA\u003c/em\u003e were significantly decreased when both drugs were administered together. Similar to the results shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eA, the addition of 1/4 and 1/2 MIC emodin in the culture medium exhibited great significance in the transcript levels of \u003cem\u003eclfA\u003c/em\u003e and \u003cem\u003eatlA\u003c/em\u003e (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eAnalysis of slime production\u003c/h2\u003e \u003cp\u003eIn \u003cem\u003eS. aureus\u003c/em\u003e, the production of slime, which encompasses polysaccharide substrates, is intricately associated with the formation of biofilms. When Congo Red interacts with these polysaccharide substrates, it elicits a color transformation from red to black upon incubation. The findings revealed that the black pigmentation surrounding the colonies remained unaltered across varying concentrations of emodin (Supplementary Fig.\u0026nbsp;1) and when emodin was combined with 1/8 MIC Amp. However, a notably discernible reduction in coloration was observed when the colonies were treated with a combination of emodin and 1/4 MIC of Amp (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eA-D).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eQualitative analysis of proteins in EPS\u003c/h3\u003e\n\u003cp\u003eEPS is a complex mixture primarily composed of polysaccharides, proteins, lipids, and nucleic acids. These components interact to form a highly hydrated and dynamic matrix that provides structural support and functional properties to the biofilm. The adhesive properties of EPS enable bacteria to adhere to surfaces, forming the foundation for biofilm development. To further understand the role of proteins in EPS, Micro BCA Protein Assay was used to compare the content of proteins between the different treatment of the antimicrobial drugs. As shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eE, a notable decrease in the amount of protein was observed in MRSA cells treated with 1/4 to 1/2 MIC emodin, compared to cells treated only with Amp in each group (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001).\u003c/p\u003e\n\u003ch3\u003eQualitative analysis of eDNA release and autolysis assay\u003c/h3\u003e\n\u003cp\u003eAccording to previous studies, eDNA, which is released through the autolysis of a small population of biofilm cells, constitutes a critical substrate in biofilms during the initial bacterial adhesion and surface aggregation. In this study, a notable decrease in the amount of eDNA release was observed in MRSA 19\u0026thinsp;\u0026minus;\u0026thinsp;10 cells treated with emodin at concentrations ranging from 1/4 to 1 MIC, compared to control cells (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003eA). The amounts of eDNA in the cell-free supernatants from biofilms treated with the combination of antimicrobial agents were shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003eB. Remarkably, a great reduction observed in eDNA release from biofilms was observed when treated with 1/4 to 1/2 MIC emodin, compared to cells treated only with Amp in each group (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001). To further assess the effect of emodin, MRSA 19\u0026thinsp;\u0026minus;\u0026thinsp;10 cells were treated with various concentrations of emodin, and the rate of autolysis induced by the nonionic detergent Triton X-100 was compared an untreated control culture (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003eC). After 210 min, the OD\u003csub\u003e600\u003c/sub\u003e values of the cells treated with 1/8 MIC, 1/4 MIC, 1/2 MIC and 1 MIC emodin were 73.30%, 73.46%, 80.16% and 81.94% of the initial value, respectively. In contrast, the control group displayed highly active autolysis, with an OD\u003csub\u003e600\u003c/sub\u003e value of 65.27%.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eThe remarkable tolerance of bacteria in biofilms to antibiotics, host defense, nutritional deficiency and heat shock underscores the urgent need for the development of antibacterial agents or treatment options to address the chronic and recurrent infections that they cause. With advanced methodologies for separation and isolation procedures, an increasing number of natural products from plants have been considered candidates for biofilm-associated infections. In the current study, emodin alone or in combination with Amp was found to exhibit anti-MRSA biofilm activity through the downregulation of biofilm-related genes (\u003cem\u003eicaA\u003c/em\u003e, \u003cem\u003efnbpB\u003c/em\u003e, \u003cem\u003eclfA\u003c/em\u003e and \u003cem\u003eatlA\u003c/em\u003e).\u003c/p\u003e \u003cp\u003eβ-lactam antibiotics have traditionally been the preferred treatment for serious invasive infections caused by \u003cem\u003eS. aureus\u003c/em\u003e until the emergence of MRSA, which has acquired a genetic element called \u003cem\u003emecA\u003c/em\u003e. \u003cem\u003emecA\u003c/em\u003e encodes an alternative penicillin-binding protein 2a (PBP2a) with diminished affinity for β-lactam antibiotics. However, MRSA susceptible to combinations of a β-lactam and compounds that disrupt the essential scaffold for PBP2a integrity \u003csup\u003e\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e. Consequently, we have selected Amp as a therapeutic partner for emodin to combat MRSA biofilm activity. Our intention is to augment the anti-MRSA biofilm efficacy of the two antimicrobial agents by employing a combination therapy strategy.\u003c/p\u003e \u003cp\u003eA previous study had already investigated the effects of emodin on biofilm formation of \u003cem\u003eS. aureus\u003c/em\u003e CMCC26003, a standard MSSA strain \u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e. However, the antibiofilm activity of emodin alone or in combination with β-lactam antibiotics against MRSA is poorly understood. The MIC of emodin against \u003cem\u003eS. aureus\u003c/em\u003e was reported to be 8 \u0026micro;g/ml and 7.8 \u0026micro;g/ml in previous studies \u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e. In this work, the MIC against MRSA planktonic cells was 16 or 32 \u0026micro;g/ml (Table\u0026nbsp;\u003cspan refid=\"Tab1\" class=\"InternalRef\"\u003e1\u003c/span\u003e). This discrepancy in MIC values may be attributed to the varying bioactivity of emodin yielded by different manufacturers and distinct gene backgrounds. It is well known that MRSA is generally more resistant to antibiotics compared to MSSA \u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e. Our results showed that emodin exhibited a concentration-dependent antibiofilm efficacy against all tested strains and showed a greater inhibition in the formation of biofilms at the same fold of MIC than that of Amp (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA and \u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB). As shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003e, the combination of 1/4 MIC or 1/2 MIC Amp plus 1/2 MIC emodin significantly affected the biofilm formation of the tested strains. Importantly, the biofilms formed by MRSA strain 19\u0026thinsp;\u0026minus;\u0026thinsp;13 at all tested concentrations were significantly lower (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001) compared to the untreated controls. Therefore, we believed that emodin is capable of sensitizing Amp to MRSA biofilm formation in a dose-dependent manner.\u003c/p\u003e \u003cp\u003eIn the clinic, biofilm-associated infections always occur without prevention \u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e. Once biofilms have formed completely, they become more challenging to eradicate, requiring higher concentrations of antimicrobial agents due to the blocked diffusion \u003csup\u003e\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e\u003c/sup\u003e. Our findings, as indicated by crystal violet quantification, revealed that emodin was able to eradicate 28.55% of MRSA strain 19\u0026thinsp;\u0026minus;\u0026thinsp;10 and 34.75% of MRSA strain 19\u0026thinsp;\u0026minus;\u0026thinsp;13 mature biofilms only at 1/4-fold MIC. Beyond this concentration, the eradication effects became more pronounced, and statistical significance (p\u0026thinsp;\u0026lt;\u0026thinsp;0.001) were observed. Additionally, an escalating inhibition ration against mature biofilms was observed with the increasing concentrations of both antimicrobial agents in MRSA strain. While the addition of 1/2 MIC emodin was enough to eradicate preformed biofilms, even a higher concentration of Amp (from 1/8 to 1/2 MIC) was required in MRSA strain 19\u0026thinsp;\u0026minus;\u0026thinsp;13.\u003c/p\u003e \u003cp\u003eTo explore the molecular mechanism of emodin, the gene expression profiles of cells that were not treated and cells that were treated with emodin were compared using real-time qPCR analysis. \u003cem\u003eStaphylococcal\u003c/em\u003e biofilms are surrounded by a self-produced extracellular matrix that consists of proteins, eDNA and polysaccharide intercellular adhesion (PIA). PIA synthesis is mediated by the \u003cem\u003eica\u003c/em\u003e operon. Therefore, downregulating \u003cem\u003eica\u003c/em\u003e gene expression could be an effective strategy to prevent \u003cem\u003eS. aureus\u003c/em\u003e biofilm formation \u003csup\u003e\u003cspan citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u003c/sup\u003e. Nevertheless, it has been reported that MRSA strains can exhibit an \u003cem\u003eica\u003c/em\u003e-independent biofilm phenotype in vitro, while clinical MSSA isolates have been identified as PNAG-dependent biofilm phenotype \u003csup\u003e\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e\u003c/sup\u003e. Moreover, most MRSA biofilms consist of eDNA and adhesins, whereas MSSA strains typically form biofilms that contain polysaccharides in their matrices \u003csup\u003e\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. In our study, the CRA plate assay demonstrated that emodin had no discernible effect on slime production unless it was co-administered with 1/4 MIC Amp (Supplementary Table\u0026nbsp;1 and Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eA-D). This finding was in accordance with the observation of a slight decrease in \u003cem\u003eica\u003c/em\u003e expression within the emodin-treated groups when Ampicillin was present at a sub-MIC level.\u003c/p\u003e \u003cp\u003eMicrobial surface components recognizing adhesive matrix molecules (MSCRAMMs), such as fibronectin-binding proteins (Fnbps) and clumping factor A (ClfA), have been known to play an important role in the initial stage of biofilm formation \u003csup\u003e\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e,\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u003c/sup\u003e. Interestingly, Fnbps have been shown to compensate for the absence of PIA in facilitating biofilm formation in the \u003cem\u003eicaADBC\u003c/em\u003e-independent biofilm phenotypes \u003csup\u003e\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e\u003c/sup\u003e. Moreover, this Fnbp-mediated biofilm is particularly common among highly virulent MRSA isolates, highlighting the significance of PIA-independent biofilm formation in MRSA strains. The micro-BCA method, derived from the established BCA method, exhibits enhanced sensitivity and is particularly well-suited for low-dose determinations. Our findings revealed a decreasing trend in the total protein content of EPS with an increasing concentration of emodin, within the sub-MIC range of Amp (as illustrated in the Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eE). Consistent with previous studies \u003csup\u003e\u003cspan additionalcitationids=\"CR39\" citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e, our results demonstrated that increased expression levels of \u003cem\u003efnbpB\u003c/em\u003e were associated with a reduction in biofilm formation. As shown in Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003e, the transcriptional levels of \u003cem\u003eclfA\u003c/em\u003e, which shared 25% sequence identity with \u003cem\u003efnbpB\u003c/em\u003e in its A domain, were decreased by emodin in a dose-dependent manner.\u003c/p\u003e \u003cp\u003eThe importance of eDNA within biofilms potentially hinges on its multifaceted roles: facilitating antibiotic resistance mechanisms, guiding nutrient localization during periods of starvation, and serving as a reservoir for the gene pool that enables horizontal gene transfer \u003csup\u003e\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e,\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e\u003c/sup\u003e. In the case of MRSA strains, eDNA release in biofilms is predominantly mediated by the autolysin protein AtlA, which is produced when a small population of biofilm cells undergo autolysis \u003csup\u003e\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e\u003c/sup\u003e. Initially described as a secreted enzyme responsible for maintaining cell wall metabolism during cell division and growth, AtlA\u0026rsquo;s participation in biofilm development has been demonstrated in various biofilm models \u003csup\u003e\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e\u003c/sup\u003e. The role of AtlA-mediated lysis in biofilm development was revealed in some biofilm models \u003csup\u003e\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e\u003c/sup\u003e. In our study, we observed a significant 7.1- and 4.2-fold decrease in the expression of the \u003cem\u003eatlA\u003c/em\u003e gene when exposing the cells to a concentration of only 1/4 MIC emodin (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003e), both in the absence or presence of 1/2 MIC Amp, aligning with the observed changes in eDNA levels (Fig.\u0026nbsp;\u003cspan refid=\"Fig8\" class=\"InternalRef\"\u003e8\u003c/span\u003e).\u003c/p\u003e \u003cp\u003ePharmacological investigations have underscored the therapeutic promise of emodin in traditional medicine for managing conditions such as inflammation and cancer. Concurrently, accumulating evidence of its organ-specific toxicity, particularly hepatotoxicity and nephrotoxicity, had prompted heightened safety concerns in clinical applications \u003csup\u003e\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e,\u003cspan citationid=\"CR46\" class=\"CitationRef\"\u003e46\u003c/span\u003e\u003c/sup\u003e. Concomitant administration of two or more pharmacological agents, synergistically augment treatment efficacy while attenuating systemic toxicities. This combinatorial strategy confers multifaceted benefits, including enhanced therapeutic index, reduced risk of drug resistance development, and improved patient compliance through tailored dosing paradigms. Our study, which investigated the combinatorial anti-biofilm activity of emodin and ampicillin against MRSA through a synergistic administration paradigm, constituted an exploratory approach to concurrent drug delivery strategies. On the other hand, nanotechnology-based drug delivery platforms have emerged as revolutionizing pharmaceutics by enhancing drug solubility, improving biocompatibility, extending circulation duration, and reducing toxicity through targeted design. A recent study demonstrated that the in situ delivery of emodin via Pluronic F-127 not only enhances its aqueous solubility but also enables targeted, prolonged release at the targeted site \u003csup\u003e\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e\u003c/sup\u003e. Subsequently, we will aim to elucidate the pronounced anti-biofilm efficacy of emodin through a targeted nanoparticle delivery system.\u003c/p\u003e \u003cp\u003eIn summary, the present work demonstrated the potential of emodin, an anthraquinone derived from \u003cem\u003eR. palmatum\u003c/em\u003e, to prevent biofilm formation and disrupt the mature biofilm of MRSA strains alone or in combination with Amp. This inhibitory effect was observed through the downregulation of \u003cem\u003efnbpB\u003c/em\u003e, \u003cem\u003eclfA\u003c/em\u003e and \u003cem\u003eatlA\u003c/em\u003e genes. Unfortunately, to date, no reliable animal model of biofilm infection has been established, which has precluded us from further validating the synergistic anti-MRSA biofilm infection effect of emodin and ampicillin in vivo. This limitation will be a critical focus of our future research endeavors.\u003c/p\u003e "},{"header":"Methods","content":"\u003ch2\u003eEthical statement\u003c/h2\u003e\n\u003cp\u003eEthical permission was approved by the Ethics Committee of Hangzhou Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, with the reference No. 2019SQ011. Participants provided written informed consent to participate in this study. All methods were carried out in accordance with relevant guidelines and regulations.\u003c/p\u003e\n\u003ch2\u003eBacterial strains and reagents\u003c/h2\u003e\n\u003cp\u003eIn this study, all \u003cem\u003eS. aureus\u003c/em\u003e isolates were collected from patients at the local hospital in Hangzhou city. The antibiotic resistance profiles of these isolates were tested against 16 drugs, as recommended by the Clinical and Laboratory Standards Institute (CLSI) criteria. Three MRSA strains, exhibited resistance to oxacillin with a MIC of 8 \u0026mu;g/ml and were subsequently identified as MRSA through detection of the specific \u003cem\u003emecA\u003c/em\u003e gene. Bacterial stocks of each strain were maintained at -80\u0026deg;C in tryptic soy broth (TSB) containing 20% glycerol (v/v). To initiate experiments, all the strains were thawed and subcultured in tryptic soy agar (TSA) for 18-24 hours.\u003c/p\u003e\n\u003cp\u003eEmodin and ampicillin (Amp) were obtained from Sangon Biotech (Shanghai, China) and prepared as stock solutions in DMSO (Sigma-Aldrich, St. Louis, Missouri, USA) and ultrapure water, respectively.\u003c/p\u003e\n\u003ch2\u003eAntimicrobial activity of S. aureus in suspension\u003c/h2\u003e\n\u003cp\u003eThe MICs and MBCs were determined using twofold dilutions. The MIC was expressed as the lowest concentration that showed no visible growth in the medium. The MBC was defined as the lowest concentration that showed no microbial growth on agar. Each isolate in each drug was tested in triplicate.\u003c/p\u003e\n\u003ch2\u003eInteractions between Amp and emodin against S. aureus in suspension\u003c/h2\u003e\n\u003cp\u003eA checkerboard microdilution method was employed to examine the combined efficacy of Amp and emodin against MRSA. Serial twofold dilutions were prepared in Mueller Hinton (MH) broth, covering a range from 1/32- to 4-fold MIC for Amp, and from 1/64- to 2-fold MIC for emodin. The 96-well plates were incubated at 37\u0026deg;C for 18-24 hours. To evaluate the effect of the combination, the fractional inhibitory concentration index (FICI) was computed using the following formula \u003csup\u003e48\u003c/sup\u003e:\u003c/p\u003e\n\u003cp\u003eFICI\u003csub\u003eA\u003c/sub\u003e= MIC of A in combination/MIC of A alone\u003c/p\u003e\n\u003cp\u003eFICI= FICI\u003csub\u003eAmp\u003c/sub\u003e + FICI\u003csub\u003eEmodin\u003c/sub\u003e\u003c/p\u003e\n\u003cp\u003eFICI\u0026le;0.5, synergy; 0.5\u0026lt; FICI\u0026le;4.0, indifference; FICI \u0026gt;4.0, antagonism.\u003c/p\u003e\n\u003ch2\u003eEstablishment of biofilms\u003c/h2\u003e\n\u003cp\u003eBiofilm formation was measured as previously described \u003csup\u003e31\u003c/sup\u003e. Briefly, individual clones were cultivated in TSB and incubated in an orbital shaker (180 rpm) at 37\u0026deg;C for 6 hours. One percent of the \u003cem\u003eS. aureus\u003c/em\u003e culture was used for all assays. The bacterial cultures were adjusted to a turbidity of 0.5 McFarland scale using phosphate buffered saline (PBS). Subsequently, the cultures were diluted 1:100 into TSB supplemented with 0.5% glucose and added to each well of a sterile 96-well flat-bottom microtiter plate (Corning Incorporated, Corning, New York, USA), which was incubated at 37\u0026deg;C for 40-48 hours under static conditions. Following incubation, the planktonic cells were removed by washing, and the remaining adherent bacterial cells in each well were stained with 100 \u0026micro;l of 0.1% crystal violet solution (Sangon Biotech, Shanghai, China). To dissolve the plates, 100 \u0026micro;l of 33% glacial acetic acid (v/v) was added to per well, and the absorption was subsequently measured at 490 nm using an iMark microplate absorbance reader (Bio-Rad Laboratories, Hercules, California, USA).\u003c/p\u003e\n\u003ch2\u003eAntimicrobial activity of S. aureus in biofilms\u003c/h2\u003e\n\u003cp\u003eCultivated biofilms were gently washed with PBS to remove planktonic cells, and then incubated for an additional 24 hours at 37\u0026deg;C in the presence of antimicrobial agents. Subsequently, the antimicrobial drugs were then removed and the biofilms were washed. PBS-treated biofilms were served as a positive control. The biofilms on the bottom were scrapped and washed with 250 \u0026micro;l PBS, while the contents of wells (10 \u0026micro;l) were mixed with warm MH broth and incubated for 24 hours at 37\u0026deg;C. The MBIC was defined as the lowest concentration that inhibited visible growth of the bacteria in the medium. The samples that exhibited no growth on agar at the lowest concentration were recorded as the MBBC \u003csup\u003e49\u003c/sup\u003e.\u003c/p\u003e\n\u003ch2\u003eBiofilm disruption\u003c/h2\u003e\n\u003cp\u003eTo determine the impacts on mature biofilms, \u003cem\u003eS.\u003c/em\u003e\u003cem\u003e \u003c/em\u003e\u003cem\u003eaureus\u003c/em\u003e was allowed to form biofilms on 96-well plates in the absence of the aforementioned drugs. Subsequently, the nonadherent cells were removed, and fresh TSB+0.5% glucose media, along with various concentrations of agents, were added to each well independently or in combination for an additional 40-48 hours at 37\u0026deg;C. The amounts within biofilms were quantified using crystal violet staining as described above.\u003c/p\u003e\n\u003ch2\u003eScanning electron microscopy assay\u003c/h2\u003e\n\u003cp\u003eMRSA cells (1.0 \u0026times; 10\u003csup\u003e6\u003c/sup\u003e CFU/ml) were cultivated in fresh TSB+0.5% glucose media, housed in 12-well plates with glasses coverslips. Various sub-MIC concentrations of emodin, along with 1/4 MIC of Amp, were introduced into the wells and incubated at 37 \u0026deg;C. Following an incubation period ranging from 40 to 48 hours, the supernatant was discarded, and the biofilms were washed gently with PBS. Subsequently, 2.5% glutaraldehyde was administered to fix the biofilms at 4 \u0026deg;C overnight. After washing with PBS, the samples were dehydrated through a series of ethanol concentrations (30%, 50%, 70%, 80%, 95%, and 100%), with each step lasting 10 min each. Finally, the samples were coated with gold and examined using a scanning electron microscope (Hitachi Regulus8100, Tokyo, Japan).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eRNA isolation and real-time PCR analysis\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eBacterial cells scraped from MRSA biofilms that were treated with antimicrobial agents alone or in combination, were suspended in 25 \u0026micro;g/ml lysostaphin (Sigma-Aldrich, St. Louis, Missouri, USA) and incubated at 37\u0026deg;C for 3 hours. Then, RNA extraction was performed using the RNeasy Mini Kit (Qiagen, Dusseldorf, Germany) according to the manufacturer\u0026rsquo;s instructions. The concentration of RNA was quantified using a NanoDrop spectrophotometer. cDNA was obtained by transcription of 150 ng of the total RNA using PrimeScript\u0026trade; RT Master Mix (Takara, Tokyo, Japan). Real-time PCR analysis was performed on a thermal cycler (Roche Group, Basel, Switzerland) for the genes \u003cem\u003eicaA\u003c/em\u003e, \u003cem\u003efnbpB\u003c/em\u003e, \u003cem\u003eclfA\u003c/em\u003e and \u003cem\u003eatlA\u003c/em\u003e using PCR mix (Takara, Tokyo, Japan) at a predefined ratio. Cycle threshold (Ct) values of all the tested genes were normalized using the Ct value of the housekeeping gene \u003cem\u003egyrB\u003c/em\u003e (\u003cem\u003egyrase B\u003c/em\u003e). Finally, the expression levels were quantified by the 2\u003csup\u003e(\u0026ndash;\u0026Delta;\u0026Delta;Ct)\u003c/sup\u003e method \u003csup\u003e39\u003c/sup\u003e. Primer sequences of the genes used in this study are given in Supplementary Table S1.\u003c/p\u003e\n\u003ch2\u003eSlime production assay\u003c/h2\u003e\n\u003cp\u003eSlime production assays were conducted using Congo Red agar (CRA), as previously described \u003csup\u003e50\u003c/sup\u003e.Congo red agar (CRA) plates consisted of brain-heart infusion (37 g/L), sucrose (36 g/L), and agar (15 g/L). After autoclaving the medium, the separated Congo Red dye (0.8 g/L) , together with control and the antimicrobial drugs were added to the agar medium when the temperature was cooled to 55 \u0026deg;C. The mixture was then poured into plates and allowed to solidify for use. Overnight cultures of MRSA cells (10 \u0026mu;l) were dropped on CRA plates and incubated for 24 h at 37 \u0026deg;C before imaging. Three independent experiments were conducted.\u003c/p\u003e\n\u003ch2\u003eEPS extraction and analysis\u003c/h2\u003e\n\u003cp\u003eThe EPS was extracted by using a modified method as described \u003csup\u003e51\u003c/sup\u003e. Briefly, the biofilms of \u003cem\u003eS. aureus\u003c/em\u003e were grown in 96-well microtiter plates (Corning, Costar, USA) treated with different concentrations of emodin or a combination with ampicillin for 24 hours. The medium was discarded, and the biofilms was washed with PBS before dissolved in PBS solution to prepare EPS. Protein in EPS extractions was determined quantitatively using the Micro BCA Protein Assay Kit (Sangon Biotech, Shanghai, China) according to the manufacturer.\u003c/p\u003e\n\u003ch2\u003eExtraction of eDNA\u003c/h2\u003e\n\u003cp\u003eeDNA was extracted from biofilms and quantified using a modified version of the method described in a previous study. Briefly, the biofilms of \u003cem\u003eS.\u003c/em\u003e\u003cem\u003e \u003c/em\u003e\u003cem\u003eaureus\u003c/em\u003e were grown on 6-well plates and treated with either emodin alone or a combination with ampicillin for 24 hours. After chilling at 4\u0026deg;C for 1 hour, 10 \u0026mu;l 0.5 M EDTA was added. The medium was discarded, and the unwashed biofilms were scraped and resuspended in Tris-EDTA (TE) buffer (10 mM Tris, 1 mM EDTA). The suspension was vigorously vortexed for 1 hour. After centrifugation (14000 rpm for 10 min), the supernatants were transferred to new tubes, and the remaining bacteria were removed via a 0.22 \u0026mu;m filter (Millipore Corporation, Billerica, Massachusetts, USA). The filtered supernatants were subjected to 1.5% (w/v) agarose gel electrophoresis and quantified by mixing 10 \u0026mu;l of supernatant with fluorescent dyes from Qubit (Invitrogen Life Technologies, Carlsbad, California, USA) for quantifying the DNA. The fluorescence of the DNA-dye interaction was measured using a Qubit 2.0 Fluorometer according to the manufacturer\u0026apos;s instructions.\u003c/p\u003e\n\u003ch2\u003eTriton X-100-induced autolysis assays\u003c/h2\u003e\n\u003cp\u003eConcentrations of 1/8 MIC, 1/4 MIC, 1/2 MIC or 1 MIC emodin were added to the cultures when the MRSA strain reached an optical density at 600 nm (OD\u003csub\u003e600\u003c/sub\u003e) of 0.3. The cultures were then incubated with shaking at 37\u0026deg;C until the OD\u003csub\u003e600\u003c/sub\u003e reached 0.7 in control cultures. The cells, including those treated with emodin, were harvested by centrifugation and washed once with cold distilled PBS. The resulting cell pellet was resuspended in 0.05 M Tris\u0026ndash;HCl (pH 7.0) containing 0.05% (v/v) Triton X-100. Afterwards, the cell suspension was then incubated at 37\u0026deg;C with shaking, and the OD\u003csub\u003e600\u003c/sub\u003e was determined at various time intervals.\u003c/p\u003e\n\u003ch2\u003eData availability\u003c/h2\u003e\n\u003cp\u003eAll data generated or analyzed during this study are included in this published article and its supplementary information files.\u003c/p\u003e\n\u003ch2\u003eStatistical analysis\u003c/h2\u003e\n\u003cp\u003eAll experiments were carried out in triplicate, and values are presented as the mean \u0026plusmn; standard deviation (SD). Statistical analysis was performed using Student\u0026rsquo;s t-test (*p \u0026lt; 0.05, **p \u0026lt; 0.01, ***p \u0026lt; 0.001).\u003c/p\u003e"},{"header":"Declarations","content":"\u003ch2\u003eAcknowledgements\u003c/h2\u003e\n\u003cp\u003eThis work was supported by Zhejiang Provincial Natural Science Foundation of China (Grant No. ZCLTGY24H2001 to Q.C.), the National Natural Science Foundation of China (Grant No. 81700768 to Q.C.), and the Special Supporting Program of Agriculture and Social Development from Hangzhou Municipal Science \u0026amp; Technology Bureau (Grant No.202203B34 to Q.C.).\u003c/p\u003e\n\u003ch2\u003eAuthor contributions\u003c/h2\u003e\n\u003cp\u003eQ.C. designed the experiments. Q.C. performed data analysis. Q.C. and M.Y.Z. performed the experiments. Q.C., F.H.C. W.Y. and T.Y. critically revised the paper. Q.C. supervised the project.\u0026nbsp;Q.C. wrote the manuscript. All authors approved the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e\u003cem\u003eAdditional Information\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting Interests:\u003c/strong\u003e The authors declare no competing interests.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n\u003cli\u003eHowden, B. P.\u003cem\u003e et al.\u003c/em\u003e Staphylococcus aureus host interactions and adaptation. \u003cem\u003eNat Rev Microbiol\u003c/em\u003e \u003cstrong\u003e21\u003c/strong\u003e, 380-395 (2023).\u003c/li\u003e\n\u003cli\u003eKosmeri, C., Giapros, V., Serbis, A., Balomenou, F. \u0026amp; Baltogianni, M. Antibiofilm Strategies in Neonatal and Pediatric Infections. \u003cem\u003eAntibiotics (Basel)\u003c/em\u003e \u003cstrong\u003e13\u003c/strong\u003e2024).\u003c/li\u003e\n\u003cli\u003eBhattacharya, M., Wozniak, D. J., Stoodley, P. \u0026amp; Hall-Stoodley, L. Prevention and treatment of Staphylococcus aureus biofilms. \u003cem\u003eExpert Rev Anti Infect Ther\u003c/em\u003e \u003cstrong\u003e13\u003c/strong\u003e, 1499-1516 (2015).\u003c/li\u003e\n\u003cli\u003eHowlin, R. P.\u003cem\u003e et al.\u003c/em\u003e Antibiotic-loaded synthetic calcium sulfate beads for prevention of bacterial colonization and biofilm formation in periprosthetic infections. \u003cem\u003eAntimicrob Agents Chemother\u003c/em\u003e \u003cstrong\u003e59\u003c/strong\u003e, 111-120 (2015).\u003c/li\u003e\n\u003cli\u003eFlemming, H. C.\u003cem\u003e et al.\u003c/em\u003e Biofilms: an emergent form of bacterial life. \u003cem\u003eNat Rev Microbiol\u003c/em\u003e \u003cstrong\u003e14\u003c/strong\u003e, 563-575 (2016).\u003c/li\u003e\n\u003cli\u003eSuresh, M. K., Biswas, R. \u0026amp; Biswas, L. An update on recent developments in the prevention and treatment of Staphylococcus aureus biofilms. \u003cem\u003eInt J Med Microbiol\u003c/em\u003e \u003cstrong\u003e309\u003c/strong\u003e, 1-12 (2019).\u003c/li\u003e\n\u003cli\u003eCraft, K. M., Nguyen, J. M., Berg, L. J. \u0026amp; Townsend, S. D. Methicillin-resistant Staphylococcus aureus (MRSA): antibiotic-resistance and the biofilm phenotype. \u003cem\u003eMedchemcomm\u003c/em\u003e \u003cstrong\u003e10\u003c/strong\u003e, 1231-1241 (2019).\u003c/li\u003e\n\u003cli\u003eFitzpatrick, F., Humphreys, H. \u0026amp; O\u0026apos;Gara, J. P. Environmental regulation of biofilm development in methicillin-resistant and methicillin-susceptible Staphylococcus aureus clinical isolates. \u003cem\u003eJ Hosp Infect\u003c/em\u003e \u003cstrong\u003e62\u003c/strong\u003e, 120-122 (2006).\u003c/li\u003e\n\u003cli\u003eMlynek, K. D.\u003cem\u003e et al.\u003c/em\u003e Effects of Low-Dose Amoxicillin on Staphylococcus aureus USA300 Biofilms. \u003cem\u003eAntimicrob Agents Chemother\u003c/em\u003e \u003cstrong\u003e60\u003c/strong\u003e, 2639-2651 (2016).\u003c/li\u003e\n\u003cli\u003eFait, A., Silva, S. F., Abrahamsson, J. A. H. \u0026amp; Ingmer, H. Staphylococcus aureus response and adaptation to vancomycin. \u003cem\u003eAdv Microb Physiol\u003c/em\u003e \u003cstrong\u003e85\u003c/strong\u003e, 201-258 (2024).\u003c/li\u003e\n\u003cli\u003eDi Domenico, E. G.\u003cem\u003e et al.\u003c/em\u003e Microbial biofilm correlates with an increased antibiotic tolerance and poor therapeutic outcome in infective endocarditis. \u003cem\u003eBMC Microbiol\u003c/em\u003e \u003cstrong\u003e19\u003c/strong\u003e, 228 (2019).\u003c/li\u003e\n\u003cli\u003eOliva, A., Stefani, S., Venditti, M. \u0026amp; Di Domenico, E. G. Biofilm-Related Infections in Gram-Positive Bacteria and the Potential Role of the Long-Acting Agent Dalbavancin. \u003cem\u003eFront Microbiol\u003c/em\u003e \u003cstrong\u003e12\u003c/strong\u003e, 749685 (2021).\u003c/li\u003e\n\u003cli\u003eTremblay, S., Lau, T. T. \u0026amp; Ensom, M. H. Addition of rifampin to vancomycin for methicillin-resistant Staphylococcus aureus infections: what is the evidence? \u003cem\u003eAnn Pharmacother\u003c/em\u003e \u003cstrong\u003e47\u003c/strong\u003e, 1045-1054 (2013).\u003c/li\u003e\n\u003cli\u003eSmith, K., Perez, A., Ramage, G., Gemmell, C. G. \u0026amp; Lang, S. Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. \u003cem\u003eInt J Antimicrob Agents\u003c/em\u003e \u003cstrong\u003e33\u003c/strong\u003e, 374-378 (2009).\u003c/li\u003e\n\u003cli\u003eDhand, A.\u003cem\u003e et al.\u003c/em\u003e Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding. \u003cem\u003eClin Infect Dis\u003c/em\u003e \u003cstrong\u003e53\u003c/strong\u003e, 158-163 (2011).\u003c/li\u003e\n\u003cli\u003eMiro, J. M.\u003cem\u003e et al.\u003c/em\u003e High-dose daptomycin plus fosfomycin is safe and effective in treating methicillin-susceptible and methicillin-resistant Staphylococcus aureus endocarditis. \u003cem\u003eAntimicrob Agents Chemother\u003c/em\u003e \u003cstrong\u003e56\u003c/strong\u003e, 4511-4515 (2012).\u003c/li\u003e\n\u003cli\u003eKullar, R.\u003cem\u003e et al.\u003c/em\u003e A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. \u003cem\u003eJ Antimicrob Chemother\u003c/em\u003e \u003cstrong\u003e68\u003c/strong\u003e, 2921-2926 (2013).\u003c/li\u003e\n\u003cli\u003eRevest, M.\u003cem\u003e et al.\u003c/em\u003e New in vitro and in vivo models to evaluate antibiotic efficacy in Staphylococcus aureus prosthetic vascular graft infection. \u003cem\u003eJ Antimicrob Chemother\u003c/em\u003e \u003cstrong\u003e71\u003c/strong\u003e, 1291-1299 (2016).\u003c/li\u003e\n\u003cli\u003eParra-Ruiz, J., Vidaillac, C., Rose, W. E. \u0026amp; Rybak, M. J. Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. \u003cem\u003eAntimicrob Agents Chemother\u003c/em\u003e \u003cstrong\u003e54\u003c/strong\u003e, 4329-4334 (2010).\u003c/li\u003e\n\u003cli\u003eCirioni, O.\u003cem\u003e et al.\u003c/em\u003e Daptomycin and rifampin alone and in combination prevent vascular graft biofilm formation and emergence of antibiotic resistance in a subcutaneous rat pouch model of staphylococcal infection. \u003cem\u003eEur J Vasc Endovasc Surg\u003c/em\u003e \u003cstrong\u003e40\u003c/strong\u003e, 817-822 (2010).\u003c/li\u003e\n\u003cli\u003eChen, Y.\u003cem\u003e et al.\u003c/em\u003e Baicalein Inhibits Staphylococcus aureus Biofilm Formation and the Quorum Sensing System In Vitro. \u003cem\u003ePLoS One\u003c/em\u003e \u003cstrong\u003e11\u003c/strong\u003e, e0153468 (2016).\u003c/li\u003e\n\u003cli\u003eBrackman, G.\u003cem\u003e et al.\u003c/em\u003e The Quorum Sensing Inhibitor Hamamelitannin Increases Antibiotic Susceptibility of Staphylococcus aureus Biofilms by Affecting Peptidoglycan Biosynthesis and eDNA Release. \u003cem\u003eSci Rep\u003c/em\u003e \u003cstrong\u003e6\u003c/strong\u003e, 20321 (2016).\u003c/li\u003e\n\u003cli\u003eAbreu, A. C., Saavedra, M. J., Simoes, L. C. \u0026amp; Simoes, M. Combinatorial approaches with selected phytochemicals to increase antibiotic efficacy against Staphylococcus aureus biofilms. \u003cem\u003eBiofouling\u003c/em\u003e \u003cstrong\u003e32\u003c/strong\u003e, 1103-1114 (2016).\u003c/li\u003e\n\u003cli\u003eRozalski, M.\u003cem\u003e et al.\u003c/em\u003e Antiadherent and antibiofilm activity of Humulus lupulus L. derived products: new pharmacological properties. \u003cem\u003eBiomed Res Int\u003c/em\u003e \u003cstrong\u003e2013\u003c/strong\u003e, 101089 (2013).\u003c/li\u003e\n\u003cli\u003eTian, N.\u003cem\u003e et al.\u003c/em\u003e Emodin mitigates podocytes apoptosis induced by endoplasmic reticulum stress through the inhibition of the PERK pathway in diabetic nephropathy. \u003cem\u003eDrug Des Devel Ther\u003c/em\u003e \u003cstrong\u003e12\u003c/strong\u003e, 2195-2211 (2018).\u003c/li\u003e\n\u003cli\u003eXing, Y. X.\u003cem\u003e et al.\u003c/em\u003e Anti-Cancer Effects of Emodin on HepG2 Cells as Revealed by (1)H NMR Based Metabolic Profiling. \u003cem\u003eJ Proteome Res\u003c/em\u003e \u003cstrong\u003e17\u003c/strong\u003e, 1943-1952 (2018).\u003c/li\u003e\n\u003cli\u003eDu, C.\u003cem\u003e et al.\u003c/em\u003e Emodin attenuates Alzheimer\u0026apos;s disease by activating the protein kinase C signaling pathway. \u003cem\u003eCell Mol Biol (Noisy-le-grand)\u003c/em\u003e \u003cstrong\u003e65\u003c/strong\u003e, 32-37 (2019).\u003c/li\u003e\n\u003cli\u003eLi, L.\u003cem\u003e et al.\u003c/em\u003e The antibacterial activity and action mechanism of emodin from Polygonum cuspidatum against Haemophilus parasuis in vitro. \u003cem\u003eMicrobiol Res\u003c/em\u003e \u003cstrong\u003e186-187\u003c/strong\u003e, 139-145 (2016).\u003c/li\u003e\n\u003cli\u003eLiu, M.\u003cem\u003e et al.\u003c/em\u003e The direct anti-MRSA effect of emodin via damaging cell membrane. \u003cem\u003eAppl Microbiol Biotechnol\u003c/em\u003e \u003cstrong\u003e99\u003c/strong\u003e, 7699-7709 (2015).\u003c/li\u003e\n\u003cli\u003eYan, X.\u003cem\u003e et al.\u003c/em\u003e The effect of emodin on Staphylococcus aureus strains in planktonic form and biofilm formation in vitro. \u003cem\u003eArch Microbiol\u003c/em\u003e \u003cstrong\u003e199\u003c/strong\u003e, 1267-1275 (2017).\u003c/li\u003e\n\u003cli\u003eChen, Q.\u003cem\u003e et al.\u003c/em\u003e Biofilm formation and prevalence of adhesion genes among Staphylococcus aureus isolates from different food sources. \u003cem\u003eMicrobiologyopen\u003c/em\u003e \u003cstrong\u003e9\u003c/strong\u003e, e00946 (2020).\u003c/li\u003e\n\u003cli\u003eShang, W.\u003cem\u003e et al.\u003c/em\u003e beta-Lactam Antibiotics Enhance the Pathogenicity of Methicillin-Resistant Staphylococcus aureus via SarA-Controlled Lipoprotein-Like Cluster Expression. \u003cem\u003emBio\u003c/em\u003e \u003cstrong\u003e10\u003c/strong\u003e, e00880-00819 (2019).\u003c/li\u003e\n\u003cli\u003eJo, A. \u0026amp; Ahn, J. Phenotypic and genotypic characterisation of multiple antibiotic-resistant Staphylococcus aureus exposed to subinhibitory levels of oxacillin and levofloxacin. \u003cem\u003eBMC Microbiol\u003c/em\u003e \u003cstrong\u003e16\u003c/strong\u003e, 170 (2016).\u003c/li\u003e\n\u003cli\u003eFeldman, M., Smoum, R., Mechoulam, R. \u0026amp; Steinberg, D. Antimicrobial potential of endocannabinoid and endocannabinoid-like compounds against methicillin-resistant Staphylococcus aureus. \u003cem\u003eSci Rep\u003c/em\u003e \u003cstrong\u003e8\u003c/strong\u003e, 17696 (2018).\u003c/li\u003e\n\u003cli\u003ePozzi, C.\u003cem\u003e et al.\u003c/em\u003e Methicillin resistance alters the biofilm phenotype and attenuates virulence in Staphylococcus aureus device-associated infections. \u003cem\u003ePLoS Pathog\u003c/em\u003e \u003cstrong\u003e8\u003c/strong\u003e, e1002626 (2012).\u003c/li\u003e\n\u003cli\u003eO\u0026apos;Neill, E.\u003cem\u003e et al.\u003c/em\u003e A novel Staphylococcus aureus biofilm phenotype mediated by the fibronectin-binding proteins, FnBPA and FnBPB. \u003cem\u003eJ Bacteriol\u003c/em\u003e \u003cstrong\u003e190\u003c/strong\u003e, 3835-3850 (2008).\u003c/li\u003e\n\u003cli\u003eO\u0026apos;Brien, L. M., Walsh, E. J., Massey, R. C., Peacock, S. J. \u0026amp; Foster, T. J. Staphylococcus aureus clumping factor B (ClfB) promotes adherence to human type I cytokeratin 10: implications for nasal colonization. \u003cem\u003eCell Microbiol\u003c/em\u003e \u003cstrong\u003e4\u003c/strong\u003e, 759-770 (2002).\u003c/li\u003e\n\u003cli\u003eZheng, Z.\u003cem\u003e et al.\u003c/em\u003e Antimicrobial activity of 1,3,4-oxadiazole derivatives against planktonic cells and biofilm of Staphylococcus aureus. \u003cem\u003eFuture Med Chem\u003c/em\u003e \u003cstrong\u003e10\u003c/strong\u003e, 283-296 (2018).\u003c/li\u003e\n\u003cli\u003eSelvaraj, A., Jayasree, T., Valliammai, A. \u0026amp; Pandian, S. K. Myrtenol Attenuates MRSA Biofilm and Virulence by Suppressing sarA Expression Dynamism. \u003cem\u003eFront Microbiol\u003c/em\u003e \u003cstrong\u003e10\u003c/strong\u003e, 2027 (2019).\u003c/li\u003e\n\u003cli\u003eValliammai, A.\u003cem\u003e et al.\u003c/em\u003e 5-Dodecanolide interferes with biofilm formation and reduces the virulence of Methicillin-resistant Staphylococcus aureus (MRSA) through up regulation of agr system. \u003cem\u003eSci Rep\u003c/em\u003e \u003cstrong\u003e9\u003c/strong\u003e, 13744 (2019).\u003c/li\u003e\n\u003cli\u003eAbdelhady, W.\u003cem\u003e et al.\u003c/em\u003e Reduced vancomycin susceptibility in an in vitro catheter-related biofilm model correlates with poor therapeutic outcomes in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. \u003cem\u003eAntimicrob Agents Chemother\u003c/em\u003e \u003cstrong\u003e57\u003c/strong\u003e, 1447-1454 (2013).\u003c/li\u003e\n\u003cli\u003eGloag, E. S.\u003cem\u003e et al.\u003c/em\u003e Self-organization of bacterial biofilms is facilitated by extracellular DNA. \u003cem\u003eProc Natl Acad Sci U S A\u003c/em\u003e \u003cstrong\u003e110\u003c/strong\u003e, 11541-11546 (2013).\u003c/li\u003e\n\u003cli\u003eMcCarthy, H.\u003cem\u003e et al.\u003c/em\u003e Methicillin resistance and the biofilm phenotype in Staphylococcus aureus. \u003cem\u003eFront Cell Infect Microbiol\u003c/em\u003e \u003cstrong\u003e5\u003c/strong\u003e, 1 (2015).\u003c/li\u003e\n\u003cli\u003eSchwartz, K., Ganesan, M., Payne, D. E., Solomon, M. J. \u0026amp; Boles, B. R. Extracellular DNA facilitates the formation of functional amyloids in Staphylococcus aureus biofilms. \u003cem\u003eMol Microbiol\u003c/em\u003e \u003cstrong\u003e99\u003c/strong\u003e, 123-134 (2016).\u003c/li\u003e\n\u003cli\u003eWang, S.\u003cem\u003e et al.\u003c/em\u003e Hepatotoxic metabolites in Polygoni Multiflori Radix- Comparative toxicology in mice. \u003cem\u003eFront Pharmacol\u003c/em\u003e \u003cstrong\u003e13\u003c/strong\u003e, 1007284 (2022).\u003c/li\u003e\n\u003cli\u003eCui, J., Wang, S., Bi, S., Zhou, H. \u0026amp; Sun, L. Emodin-based Regulation and Control of Serum Complement C5a, Oxidative Stress, and Inflammatory Responses in Rats with Urosepsis via AMPK/SIRT1. \u003cem\u003eIran J Allergy Asthma Immunol\u003c/em\u003e \u003cstrong\u003e23\u003c/strong\u003e, 550-562 (2024).\u003c/li\u003e\n\u003cli\u003eYao, Y.\u003cem\u003e et al.\u003c/em\u003e Emodin in-situ delivery with Pluronic F-127 hydrogel for myocardial infarction treatment: Enhancing efficacy and reducing hepatotoxicity. \u003cem\u003eLife Sci\u003c/em\u003e \u003cstrong\u003e354\u003c/strong\u003e, 122963 (2024).\u003c/li\u003e\n\u003cli\u003eOo, T. Z., Cole, N., Garthwaite, L., Willcox, M. D. \u0026amp; Zhu, H. Evaluation of synergistic activity of bovine lactoferricin with antibiotics in corneal infection. \u003cem\u003eJ Antimicrob Chemother\u003c/em\u003e \u003cstrong\u003e65\u003c/strong\u003e, 1243-1251 (2010).\u003c/li\u003e\n\u003cli\u003eGuo, N.\u003cem\u003e et al.\u003c/em\u003e The synergy of berberine chloride and totarol against Staphylococcus aureus grown in planktonic and biofilm cultures. \u003cem\u003eJ Med Microbiol\u003c/em\u003e \u003cstrong\u003e64\u003c/strong\u003e, 891-900 (2015).\u003c/li\u003e\n\u003cli\u003ePark, I., Lee, J. H., Ma, J. Y., Tan, Y. \u0026amp; Lee, J. Antivirulence activities of retinoic acids against Staphylococcus aureus. \u003cem\u003eFront Microbiol\u003c/em\u003e \u003cstrong\u003e14\u003c/strong\u003e, 1224085 (2023).\u003c/li\u003e\n\u003cli\u003eSalisbury, A. M., Chen, R., Mullin, M., Foulkes, L. \u0026amp; Percival, S. L. The Effects of a Concentrated Surfactant Gel on Biofilm EPS. \u003cem\u003eSurg Technol Int\u003c/em\u003e \u003cstrong\u003e36\u003c/strong\u003e, 31-35 (2020).\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":true,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"MRSA, Emodin, Ampicillin, Antibiofilm activity","lastPublishedDoi":"10.21203/rs.3.rs-5030207/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-5030207/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eMethicillin-resistant \u003cem\u003eStaphylococcus aureus\u003c/em\u003e (MRSA) is recognized as a significant global health concern. The development of resistance to a broad spectrum of antibiotics, particularly following biofilm formation, renders conventional therapeutic options for MRSA ineffective. Three MRSA clinical isolates were examined in vitro to assess their biofilm-forming capacity and the disruptive effects on pre-established biofilm (via crystal violet staining and scanning electron microscopy), and quantify extracellular DNA (eDNA) release after exposed to emodin alone or in combination with ampicillin. In addition, real-time PCR was employed to investigate the impact of emodin on the expression of biofilm-related genes in MRSA biofilms. The inhibitory effect of emodin on biofilm formation and disruption was observed in a dose dependent manner. The antagonistic activity of emodin in combination with ampicillin against MRSA biofilms was confirmed through adhesion assays. Real-time PCR analysis revealed that emodin, either alone or in combination with ampicillin, effectively downregulated the transcriptional levels of the biofilm-related genes \u003cem\u003efnbpB\u003c/em\u003e, \u003cem\u003eclfA\u003c/em\u003e and \u003cem\u003eatlA\u003c/em\u003e, but not \u003cem\u003eicaA\u003c/em\u003e. In addition, drug treatment resulted in a significant reduction in eDNA release and protein contain in EPS (extracellular polymeric substances), which corresponded to the markedly decreased transcript level of \u003cem\u003eatlA\u003c/em\u003e and \u003cem\u003efnbpB\u003c/em\u003e, respectively. These observations suggest that emodin, either alone or in combination with ampicillin, holds potential as a therapeutic approach for MRSA biofilm-related infections.\u003c/p\u003e","manuscriptTitle":"Impact of emodin alone or in combination with ampicillin on methicillin-resistant Staphylococcus aureus biofilms in vitro","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-04-23 13:56:04","doi":"10.21203/rs.3.rs-5030207/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Revision requested","date":"2025-05-23T10:49:27+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2025-05-23T08:11:32+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2025-05-23T08:11:22+00:00","index":"","fulltext":""},{"type":"editorInvitedReview","content":"","date":"2025-05-03T21:49:38+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"118280631474048470324835582706701756253","date":"2025-04-23T09:22:27+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2025-04-22T08:23:26+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-04-22T07:16:45+00:00","index":"","fulltext":""},{"type":"submitted","content":"Scientific Reports","date":"2025-04-07T14:34:36+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"scientific-reports","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"scirep","sideBox":"Learn more about [Scientific Reports](http://www.nature.com/srep/)","snPcode":"","submissionUrl":"","title":"Scientific Reports","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"stoa","reportingPortfolio":"Scientific Reports","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"1f77b481-c019-4d1c-9baa-e8cb1654f816","owner":[],"postedDate":"April 23rd, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"published-in-journal","subjectAreas":[{"id":47491893,"name":"Biological sciences/Biotechnology"},{"id":47491894,"name":"Biological sciences/Microbiology"},{"id":47491895,"name":"Health sciences/Diseases/Infectious diseases"}],"tags":[],"updatedAt":"2025-07-07T16:11:34+00:00","versionOfRecord":{"articleIdentity":"rs-5030207","link":"https://doi.org/10.1038/s41598-025-06800-5","journal":{"identity":"scientific-reports","isVorOnly":false,"title":"Scientific Reports"},"publishedOn":"2025-07-01 15:57:11","publishedOnDateReadable":"July 1st, 2025"},"versionCreatedAt":"2025-04-23 13:56:04","video":"","vorDoi":"10.1038/s41598-025-06800-5","vorDoiUrl":"https://doi.org/10.1038/s41598-025-06800-5","workflowStages":[]},"version":"v1","identity":"rs-5030207","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-5030207","identity":"rs-5030207","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}